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Immune-mediated hemolytic anemia (IMHA) is one of the most common causes
of anemia in dogs. Despite aggressive therapy, there is a 50% mortality rate in IMHA
patients, and the most common cause of death is thromboembolic disease, particularly
pulmonary thromboembolism. With the high thromboembolism rate in dogs with IMHA,
anti-platelet therapy with aspirin can be a life-saving preventative therapy. Along with
anti-platelet therapy, immunosuppressive therapy is needed to decrease erythrocyte
destruction. Cyclosporine has become a popular medication for immunosuppression in
IMHA patients. Unfortunately, recent human reports have suggested that cyclosporine
could activate platelets and contribute to a hypercoagulable state.
With the goal of improving therapy, these studies investigated the role aspirin
plays in inhibiting platelet function and cyclooxygenase expression, an enzyme that
enhances platelet reactivity. The effect of cyclosporine on platelet reactivity and
hypercoagulablity was investigated to determine if this medication would create activated
platelets and a prothrombotic state.
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CHAPTER I
INTRODUCTION
Immune-mediated hemolytic anemia (IMHA), also known as autoimmune
hemolytic anemia, is one of the most common causes of red blood cell destruction and
anemia in dogs, and is mediated by antibody and/or complement-mediated destruction of
red blood cells.1 In IMHA cases, the destruction of erythrocytes is usually associated
with a type II hypersensitivity reaction that involves anti-erythrocyte antibodies,
including IgG, IgM, and IgA, as well as complement components.2,4 Extravascular
hemolysis, or erythrophagocytosis, is typically associated with IgG antibodies and
complement components C to C3 stages (specifically C3).4 A majority of
erythrophagocytosis occurs in tissues that contain a high population of macrophages,
mainly the spleen, liver, and bone marrow.5 Intravascular erythrocyte destruction is more
commonly associated with hemolysis instead of erythrophagocytosis, and is due to the
activation of the entire complement cascade, C1 to C9. Complement fixation on the
erythrocyte membrane causes an influx of extracellular fluid, followed by red blood cell
lysis.6 Since IgM is more efficient at fixing complement proteins, intravascular IMHA is
typically an IgM-mediated disease.5,7,8
Immune-mediated hemolytic anemia can be further classified as either primary or
secondary, depending on the presence of an underlying disease. Patients diagnosed with
primary, or idiopathic, IMHA do not have an identifiable underlying condition that
1

promotes erythrocyte destruction.2 However, patients with secondary IMHA usually
develop an immunologic response to foreign antigens that have either modified or
become associated with erythrocyte membranes. Causes of secondary IMHA include
infectious diseases (bacterial, viral, rickettsial), toxins, parasites, drugs (such as sulfa
antibiotics, penicillins, and acetaminophen), vaccination, and neoplasia.1,2 Primary
IMHA is the most common form of IMHA, and 60 to 75% of all IMHA cases are
considered to be idiopathic.2
The diagnosis of secondary IMHA requires the identification of an underlying
cause; while treatment consists of the removal or treatment of the initiating cause,
followed by temporary immunosuppressive therapy. On the other hand, since patients
with primary IMHA do not have an identifiable underlying cause, the mainstay of therapy
consists of immunosuppressive therapy (using drugs such as prednisone, cyclosporine,
and azathioprine) and supportive care (for example, blood transfusion).
Unfortunately, despite the best treatment efforts, primary IMHA in dogs will
often lead to death of the patient. The mean mortality rate for primary IMHA in dogs is
approximately 50%,3,8-10 but has been reported to be as high as 70%.2 The most common
cause of death in dogs with IMHA is thromboembolic disease, particularly pulmonary
thromboembolism (PTE). Approximately 50% of dogs with IMHA have been shown to
be in a hypercoagulable state that predisposes them to complications such as PTE.2 The
incidence of PTE in dogs with IMHA has been determined to be over 30%, and may be
as high as 80%.8 Since pulmonary thromboembolism is notoriously difficult to diagnose
except at post mortem, it is even possible that the incidence of PTE in dogs with IMHA
may be higher than 80%.8
2

Even though IMHA is a common condition in dogs, and almost all patients are
predisposed to the development of thromboembolic complications, the exact mechanisms
of excessive thrombus formation are not completely understood. However, it is
hypothesized that a hypercoagulable state involving both blood platelets and clotting
factors is implicated in the development of pathologic thromboembolic diseases.2,11
Other possible factors contributing to the formation of PTE include vascular endothelial
injury and blood stasis. Since a hypercoagulable state, vascular endothelial injury and
blood stasis (so-called ‘Virchow’s triad’) are all potentially present in IMHA patients,7,8
it is hardly surprising that affected animals are prone to PTE and other thromboembolic
complications. Dogs with IMHA have been shown to have hyperactive platelets,11
suggesting that platelets may play an integral role in thrombus formation.

Platelet Formation
The formation of platelets, thrombopoiesis, occurs mainly in the bone marrow and
involves the maturation of the megakaryocyte cell line (megakaryoblast,
promegakaryocyte, and megakaryocyte).12 The terminal differentiation phase of
thrombopoiesis results in the shedding of platelets into circulation. Mature
megakaryocytes develop multiple cytoplasmic processes, proplatelets, which penetrate
into the venous sinusoids. Through a process of fragmentation, platelets are shed from
both the megakaryoctye and proplatelet, and enter circulation.12-14 Once in circulation,
the normal circulating lifespan of canine platelets is approximately five to seven days.15
Newly formed platelets that have recently been released into circulation are
known as reticulated platelets, because of the residual mRNA present within the cell.16 In
3

the circulation, reticulated platelets will continue to mature and the residual mRNA will
degrade within one day.17 The percentage of circulating reticulated platelets can reflect
megakaryocyte proliferation, and an elevated percentage of these new platelets usually
indicates accelerated platelet production, while a lower percentage suggests poor
megakaryocyte function.16
Mature platelets are anucleate cells and for this reason, it has often been stated
that platelets are not capable of de novo changes in expression of proteins in response to
endogenous or exogenous stimuli. However, since reticulated platelets contain residual
mRNA and some rough endoplasmic reticulum derived from megakaryocytes,18,19 the
intracellular molecular mechanisms necessary for protein production remain functional.17
The concentration and expression of proteins within newly formed platelets will depend
on the protein expression within the megakaryocyte. Hence, the upregulation of a
specific protein within the megakaryocyte will result in a similar increased expression in
both the reticulated and mature platelet.19 The platelet’s ability to continue to synthesize
and express proteins in a post-transcriptional level has previously been demonstrated in
human platelets that contain active mRNA that continues de novo synthesis of
plasminogen activator inhibitor 1.19

Platelet Function
Normal blood hemostasis is a complicated process that involves platelets,
vascular endothelium, numerous coagulation factors, and several interacting cells.
Hemostasis is typically broken down into three distinct phases: first, the formation of a
platelet plug through the interactions of platelets and the vessel endothelium (primary
4

hemostasis), second, the interaction of coagulation factors to form a blood clot that
strengthens the platelet plug with a cross-linked fibrin meshwork (secondary hemostasis),
and finally, the activation of plasmin to break down fibrin and remove the blood clot
(fibrinolysis). Defects in any of these phases can result in ineffective hemostasis, leading
to either excessive hemorrhage or clot formation. The formation of a temporary platelet
plug during primary hemostasis is the first step in coagulation, and plays a major role in
preventing blood loss. Unfortunately, the platelet plug is only stable for a short period of
time and, without coagulation factors for reinforcement, the plug will weaken and a blood
clot may not form. On the other hand, continual platelet activation, especially in
hypercoagulable states, will support excessive platelet plug and blood clot formation.
In circulation, platelets travel along the periphery of blood vessels in a nonactivated state. When exposed to injured or damaged endothelium, either due to normal
cell turnover or vessel trauma, platelets are activated and adhere to the damaged
endothelium.20 Activated platelets will release a multitude of agents such as serotonin,
adenosine diphosphate (ADP), prostaglandins, and thromboxane A2 (TXA2), which have
the combined effects of causing vasoconstriction, decreasing blood flow, and increasing
blood stasis.21 Disruption of the vessel endothelium and decreases in blood velocity due
to vasoconstriction result in increased contact time between activated platelets,
coagulation factors and damaged vascular subendothelium, a condition which promotes
generation of the nidus needed to initiate clot formation.
One of the main mediators in platelet-induced vasoconstriction and platelet
activation is the prostaglandin thromboxane A2. Once synthesized and released by
activated platelets, TXA2 triggers vasoconstriction, recruits and activates additional
5

platelets, and enhances platelet aggregation.22 Following synthesis by platelets,
thromboxane A2 has an immediate, but short lived effect (approximately 30 seconds).
After release, thromboxane A2 is metabolized to thromboxane B2 and further metabolized
into 11-dehydro-thromboxane B2 and 2,3-dinor-thromboxane B2 before being eliminated
in the urine.23-25
Cells, including platelets, do not store thromboxane, but the prostaglandin is
synthesized from arachidonic acid that has been released from phospholipid membranes
through the actions of several phospholipases that include phospholipase A2,
prostaglandin H synthase, and thromboxane synthase.26-28 Once mobilized, arachidonic
acid is converted into prostaglandin H2 by prostaglandin H-synthase-1 or -2, more
commonly known as cyclooxygenase (COX)-1 and –2. Both COX enzymes play key
roles in normal hemostasis, and lead to the production of several biologically active
prostaglandins, mainly thromboxane A2 and prostacyclin.27,29 Unlike thromboxane A2,
which is mainly produced by platelets to enhance aggregation, prostacyclin
(prostaglandin I2) originates from the vascular endothelium and has the opposite
physiologic effect on primary hemostasis (vasodilation and inhibiting platelet
aggregation).26,27,30 These two prostaglandins work in concert to maintain a balanced,
normal hemostatic system.
At least three COX isoforms have been described in dogs. COX-1 is
constitutively expressed in most body systems, and functions to maintain normal cellular
activities including platelet thromboxane A2 production, maintenance of gastric mucosal
protection, and preservation of renal blood flow.28,31 The COX-3 isoform is transcribed
from the COX-1 gene as a splice variant and has similar catalytic features, but only about
6

20% of the activity of COX-1.32,33 Relative to COX-1, COX-2 has a far more limited
tissue distribution, and expression is often at much lower levels. COX-2 expression
occurs in the brain, kidney, thymus and the vascular endothelium.31,34,35 COX-2 is also
present in circulating monocytes, tissue macrophages and fibroblasts.31 COX-2
expression can be induced by various endogenous and exogenous mediators including
inflammatory cytokines, growth factors, and endotoxins.28,36,37 Induction of the COX-2
enzyme occurs primarily at the post-transcriptional level.38
Since mature platelets do not contain a nucleus and are therefore incapable of
mRNA synthesis, and because COX-1 is usually constitutively expressed by cells
whereas COX-2 expression is more typically induced, it was long believed that COX-1
was the only COX isoform expressed in circulating platelets, and that COX induction
could happen only at the level of the bone marrow. As a result, it was originally believed
that COX-1 was the primary mediator of platelet thromboxane A2 production, while
COX-2 was the main isoform that controlled endothelial prostacyclin
production.26,27,35,39-41 However, a flow cytometry technique has been described that has
identified and quantified the expression of both COX-1 and COX-2 in circulating human
platelets.39 In humans, platelet COX-2 expression is greater during times of increased
platelet turnover and higher levels of reticulated platelets.29,34,42 These recent discoveries
suggest that platelet COX-2 could in fact play a role in platelet function.31,39 Nucleated
marrow platelet precursor cells, megakaryocytes, contain COX-1 and COX-2,31,42 and
changes in COX expression that are induced at the level of these platelet precursors
would be expected to result in similar changes in platelets derived from affected
megakaryocytes.
7

Platelet activation is a complicated process that involves much more than
interaction with thromboxane, and also includes a variety of agonists that stimulate and
activate platelets. Just as activated platelets release substances that cause
vasoconstriction, platelets also release agonists that attract and activate other platelets to
help form a platelet plug. Since platelets do not contain a nucleus, they are dependent on
agonists and stimuli to reach an activated state. Stored throughout the platelet are
granules, approximately 200 – 500 nm in size, that contain multiple proteins that enhance
platelet adhesion, promote cell-to-cell interactions, and stimulate vascular repair.43,44
Alpha-granules are the main secretory component of platelets, but dense (delta) granules
and lysosomes are also present in platelets.44 Substances found in α-granules include
adhesion molecules (von Willebrand factor, P-selectin, and fibronectin), pro and antiangiogenic factors (Vascular Endothelial Growth Factor) and coagulation factors
(fibrinogen, factors V and VIII), while dense granules contain adenosine diphosphate,
epinephrine, and serotonin.44 It is well established that, both during platelet formation in
the bone marrow and after being taken up by circulating platelets, molecules can be
selectively packaged within different α-granule subsets.43-47 During activation, the
release of selectively packaged proteins from platelet α-granules is dependent on specific
receptor activation and different platelet agonists.43,44,48
One of the molecules released from platelet α-granules during activation is Pselectin. Platelet P-selectin is a cell adhesion molecule that mediates platelet and
leukocyte aggregation and generates procoagulant microparticles that contain active
tissue factor and enhance fibrin deposition.49,50 Therefore, platelet P-selectin is believed
to have procoagulant effects that enhance both platelet aggregation and secondary
8

hemostasis. Platelet P-selectin expression has been shown to be expressed in higher
concentrations in canine patients with primary IMHA, and could contribute to the high
rate of thromboembolic complications seen in IMHA patients.11
Platelets play an important role in assisting the coagulation factors needed to
stabilize the platelet plug and form a blood clot. First, platelet α-granules release procoagulant factors such as factors V and VIII and fibrinogen, which enhance the clot
strength. Secondly, activated platelets will undergo a shape change, creating a greater
surface area for adherence to both the endothelium and other platelets or cells.51 Finally,
platelets will also express additional receptors and ligands on the surface to facilitate
thrombin generation and fibrin formation. In inactivated platelets, the aminophospholipid
phosphatidylserine is located in the inner leaflet of the platelet plasma membrane but,
upon activation, platelet phosphatidylserine is exposed on platelet surface membranes
and binds to prothrombin, accelerating the conversion of prothrombin to thrombin, and
expediting the formation of a blood clot.52 It is estimated that a phosphatidylserine-rich
platelet surface is capable of synthesizing thrombin 300,000 times faster than the fluid
phase of plasma.52 Phosphatidylserine expression during platelet activation occurs
primarily through the opening of the mitochondrial permeability transition pore
(MPTP).53,54 During activation, the MPTP transiently opens and releases several
activating mitochondrial contents into the cell cytoplasm, mediating caspase-3 activation
and ultimately leading to increased phosphatidylserine expression on the cell surface.55,56

9

Aspirin Therapy
Normal platelet function and activation is necessary for the prevention of
hemorrhage, but excessive platelet activation can lead to the development of large blood
clots and thromboembolic complications, especially pulmonary thromboembolism. The
risk of thromboembolism has been identified as a significant complication in many
commonly encountered diseases, and can be a devastating complication of otherwise
treatable conditions.57 Besides IMHA, there are many diseases/conditions in veterinary
medicine that are associated with an increased risk of thromboembolic complications,
including protein-losing nephropathies, hyperadrenocorticism, sepsis, disseminated
intravascular coagulation, and systemic inflammatory response syndrome.58
Diagnosing thromboembolic diseases can be very challenging. In human
medicine, the diagnosis of a thromboembolism typically involves advanced imaging
techniques that include venous compression ultrasonography and multidetector computed
tomography and magnetic resonance angiography.59 However, in veterinary medicine,
some of these diagnostic techniques are not readily available. Because of the difficulty in
establishing a definitive diagnosis in dogs, a combination of clinical signs, blood tests
(decrease in platelet count, increase in D-Dimer and fibrin degradation products
concentrations), and diagnostic imaging are needed to determine a presumptive diagnosis
of a thromboembolism. Establishing a diagnosis of thromboembolism will also depend
on the presence of an underlying disease that is associated with a hypercoagulable state.
Even with a definitive diagnosis, and the localization of a thrombus, treatment can
be difficult and have devastating, life-threatening complications. If possible, either
removal of the clot or administration of thrombolytic medications directly to the clot can
10

provide some relief and restore blood flow to the affected tissue. However, identifying
and then isolating the thrombus can be very difficult, limiting the usefulness of these
techniques. The use of systemic thrombolytic agents could be beneficial at dissolving a
thrombus and restoring blood flow to the affected tissue. Unfortunately, severe
complications can arise from systemic thrombolytic therapies which include hemorrhage,
allergic reactions, and ischemia-reperfusion injuries after thrombus dissolution.60
Because of the devastating complications associated with both a thromboembolic
event and thrombolytic treatment, preventative therapy is an essential component of
treatment of patients in a hypercoagulable state. Inhibition of both primary and
secondary hemostasis will provide the most complete preventative therapy.
Unfortunately, many of the medications used in veterinary medicine that inhibit
coagulation factors, such as heparins, can only be given by injection or are cost
prohibitive for long term administration, making anti-platelet therapy the most commonly
administered preventative therapy. The use of a safe, long term, affordable oral antiplatelet medication for the prevention of thromboembolism becomes a critical component
of therapy in patients with in a hypercoagulable state. One of the most commonly used
anti-platelet medications, aspirin, is highly effective at inhibiting both human and canine
platelet function.22,61-64
Aspirin (acetylsalicylic acid) inhibits platelet function by irreversibly acetylating
the hydroxyl group on a serine residue (position 530) located on the COX-1
enzyme.28,29,65 This acetylation will permanently block arachidonic acid from reaching
the active site of the COX enzyme, which is located between arginine 120 and tyrosine
385.65 By acetylating the COX enzyme, aspirin prevents platelet thromboxane A2
11

synthesis, and inhibits platelet activation and function.28,29,61,65 Since platelets do not
contain a nucleus, and are unable to synthesize new and functioning COX enzymes,
aspirin-induced platelet dysfunction will persist for the entire lifespan of the platelet, and
function will not return until the drug is discontinued and new platelets, not exposed to
aspirin, are released from the bone marrow.
The aspirin-induced inhibition of the COX enzyme, not only inhibits the
prostaglandins needed for platelet function, but also inhibits all prostaglandins generated
through the arachidonic acid cascade. Other than thromboxane and prostacyclin, the
COX enzyme is responsible for the conversion of prostaglandin H2 to several other
biologically active mediators, which include prostaglandin E2, prostaglandin D2, and
prostaglandin F2α. These prostaglandins play key roles in mediating inflammation, tissue
homeostasis, renal blood flow, and gastrointestinal wall protection. Besides inhibiting
thromboxane production, aspirin’s ability to inhibit the COX enzyme will also inhibit
pro-inflammatory prostaglandin synthesis, making this medication an effective antiinflammatory therapy. Unfortunately, by inhibiting the COX enzyme and decreasing
prostaglandin synthesis, especially synthesis of the protective prostaglandins E2 and D2,
aspirin can cause several life-threatening side effects that include gastrointestinal
hemorrhage and renal failure.23 An anti-inflammatory dose, or high dose, of aspirin (10
mg/kg twice daily), is very effective at consistently inhibiting platelet function, but can
lead to multiple gastrointestinal and renal side effects, which makes this aspirin dose an
undesirable preventative therapy.
A high dose of aspirin permanently inhibits COX function in all cells that express
this enzyme, including vascular endothelial cells. However, unlike the higher, anti12

inflammatory dose, a low dose of aspirin (0.5-1 mg/kg once daily) will inhibit platelet
thromboxane synthesis and function without permanently inhibiting COX function of the
vascular endothelium, allowing prostacyclin synthesis and vasodilation to continue.22
Lower doses will also eliminate the potentially devastating side effects that occur with
high dose aspirin, making low dose aspirin an appealing treatment for the prevention of
thromboembolic complications. In fact, the administration of low doses of aspirin has
been associated with an improved survival rate in dogs with IMHA.66
Unfortunately, despite preventative therapy, some dogs treated with aspirin will
continue to develop thromboembolic complications. A similar phenomenon occurs in
humans that are receiving low doses of aspirin, indicating that these patients are poorly
responsive to the anti-platelet effects of aspirin (‘aspirin resistant’). The true incidence of
aspirin resistance in humans is unknown, but the published incidence ranges from 8-45%
of human patients.61,67,68 Since canine clinic patients appear to inconsistently respond to
low dose aspirin, it is possible that, similar to humans, dogs also experience aspirin
resistance. The true incidence of aspirin resistance in dogs is, however, unknown.
The exact mechanism for aspirin resistance in both humans and dogs is also
unknown; however, there have been many proposed explanations. One proposed
mechanism is the presence of an alternate source of thromboxane.29 Since aspirin is
highly effective at inhibiting COX-1 production of thromboxane, an additional
thromboxane source would require a COX-1 independent pathway. One of the proposed
alternate pathways of thromboxane production is the COX-2 isoform, either from the
vascular endothelium or circulating platelets.29,39 In humans, the inhibition of the COX-2
enzyme requires a much higher dose of aspirin than COX-1. For example, in humans, an
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aspirin dose of 81 – 325 mg per day is adequate to inhibit COX-1 function, while >325
mg per day of aspirin is need to inhibit COX-2 function.29 Low doses of aspirin,
administered to dogs at a dose of 0.5 mg/kg per day,66 may be sufficient to inhibit COX-1
synthesis of thromboxane, but insufficient to inhibit COX-2 production of thromboxane.
A second proposed mechanism of aspirin resistance includes genetic differences
in the polymorphism of both COX-1 and COX-2, making these enzymes less sensitive to
aspirin. In humans, polymorphism of the gene that codes for platelet glycoprotein IIIa,
PLA2, has been associated with aspirin resistance.69,70 Other proposed mechanisms of
aspirin resistance include an increased reactivity to other platelet aggregating factors,
increased production of new platelets that have not been exposed to aspirin, and increased
production of isoprostanes, specifically 8-iso-PGF2α, which induce vasoconstriction and
interact with TXA2/PGH2 receptors.71 Finally, patient compliance and drug absorption
play a significant role in assessing the anti-platelet effects of aspirin.

Evaluating Platelet Function
The use of platelet aggregometry has been utilized for over 50 years to evaluate
platelet function, and has long been considered the gold standard for evaluating platelet
function.64,72,73 Aggregometry analyzes platelet function by using agonists to activate
platelets in either platelet rich plasma or whole blood, and determines the ability of
platelets to aggregate and form a platelet plug.72,73 Platelet aggregometry is, however,
expensive and requires specialized equipment and training, thus making it difficult to
utilize in a clinical setting.72
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Similar to aggregometry, the Siemens Platelet Function Analyzer-100® (PFA100®) is an instrument that evaluates platelet function, but the PFA-100 is more useful in
a clinical setting. The PFA-100® has previously been evaluated for use in dogs as a
commercial point-of-care platelet function analyzer.63,64,74 Briefly, the PFA-100® is an in
vitro platelet function analyzer that measures the time needed to form a platelet plug in an
environment similar to blood vessels. Platelet agonists such as collagen, epinephrine, and
ADP are used to activate platelets under high shear conditions. The time taken for the
activated platelets to form a plug and occlude an aperture designed to replicate damaged
vascular endothelium is measured and reported as the closure time. The PFA-100®
utilizes two types of cartridges with two platelet agonists per cartridge
(collagen/epinephrine and collagen/ADP) to evaluate platelet function. The PFA-100®
collagen/epinephrine cartridge detects drug-induced platelet dysfunction and the
collagen/ADP cartridge evaluates congenital and acquired platelet function defects.75
Prolongation of the PFA-100® closure time as measured with the collagen/epinephrine
cartridge has become well established as a sensitive indicator of aspirin-induced platelet
dysfunction in both humans and dogs.64
Thromboxane concentration is a reliable indicator of COX function, both in
hypercoagulable states and during aspirin therapy. Urinary concentrations of 11dehydro-thromboxane B2 (the most abundant urinary metabolite of thromboxane) and
2,3-dinor thromboxane B2 are increased in human diseases that are associated with a
hypercoagulable state, including atherosclerosis, myocardial infarction, post-stroke
dementia, and chronic obstructive pulmonary disease.76,77 Urinary concentrations of 11dehydro-thromboxane B2 are elevated in dogs with gastric dilatation-volvulus.76
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Measurement of urinary 11-dehydro-thromboxane B2 has been utilized in previous
studies as an indicator of aspirin-induced COX inhibition.24,77,78
Levels of thromboxane metabolites in plasma or serum can be artifactually
increased due to platelet activation during sample collection and processing. The use of
urine to measure thromboxane metabolites avoids the problem of in vitro platelet
activation associated with blood collection, and is therefore considered to be a more
reliable indicator of platelet thromboxane synthesis.24,25 Urinary thromboxane B2 can,
however, be generated by the kidneys and excreted without metabolism; consequently,
urinary thromboxane B2 concentrations may provide an inaccurate representation in vivo
platelet thromboxane A2 synthesis.76 Therefore, urinary assessment of 11-dehydrothromboxane B2 and/or 2,3-dinor thromboxane B2 are useful indicators of in vivo platelet
thromboxane production.23,76,77
Unlike instruments that evaluate platelet function, flow cytometry allows
assessment of platelets with minimal manipulation of the sample. Flow cytometry
detects fluorescence from labeled monoclonal antibodies that are bound to surface
proteins to identify and quantitate the expression of a particular protein. Unlike
aggregometry, where platelet activation is necessary, flow cytometry can evaluate surface
protein expression before and after activation. Some of the surface markers that detect
platelet activation include P-selectin, phosphatidylserine, and fibrinogen bound to
glycoprotein IIb-IIIa.79,80 Flow cytometry techniques have been developed to identify
unactivated and activated platelets as well as microparticles released from activated
platelets.11,79 Even though flow cytometry does not evaluate the platelet’s ability to form
a platelet plug, understanding which proteins are expressed during clinical diseases helps
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determines the activation status of platelets, and if there is an increased risk of
thromboembolic complications.

Cyclosporine Therapy
Treatment of IMHA in dogs typically consists of immunosuppressive medications
and supportive care. Although the cornerstone of immunosuppressive therapy for IMHA
is treatment with glucocorticoids such as prednisone, additional immunosuppressive
agents such as cyclophosphamide and azathioprine are often administered concurrently
with glucocorticoids in order to achieve an effective level of immunosuppression.
Prednisone, cyclophosphamide, and azathioprine all are commonly associated with side
effects that can be dangerous for the patient and undesirable for the owners, such as
myelosuppression with azathioprine and cyclophosphamide, hepatoxicity with
azathioprine, sterile cystitis with cyclophosphamide, and polyuria, polydipsia, polyphagia
and panting with prednisone. Side effects associated with standard immunosuppressive
agents have in recent times led to the exploration of the use of alternative
immunosuppressive agents such as cyclosporine.
Cyclosporine, a powerful immunosuppressive agent, was originally introduced
into human medicine over 30 years ago for the use in organ transplantation.
Cyclosporine is a promising drug for the treatment of immune-mediated diseases because
it typically does not have many of the severe side effects associated with other
immunosuppressive agents. Cyclosporine has slowly been adopted by the veterinary
community over the past few decades and, more recently, since the development of a
veterinary-approved cyclosporine product, has rapidly increased in popularity for the
17

treatment of a wide range of immune-mediated diseases in the dog.81-84 Cyclosporine has
been shown to be an effective, non-steroidal alternative in refractory allergic cases,85 in
immune-mediated dermatoses,81 in inflammatory bowel disease,81 and in perianal
furunculous.82-84,86 Although there have been few scientific studies that have evaluated
the effectiveness of cyclosporine in the treatment of IMHA in dogs, the
immunosuppressive agent has steadily increased in popularity for treating this particular
condition because of limited associated side effects and the perceived safety of the drug.86
Given the current high mortality rates associated with standard treatment of IMHA in the
dog, veterinarians are hoping that cyclosporine will prove to be an effective new
medication that improves survival rates and enhances safety and quality of life in patients
with IMHA.
Recent human studies, however, have shown that the administration of
cyclosporine increases the thrombogenic properties of platelets and accelerates thrombin
generation.52 In 2007, Tomasiak and others used platelet flow cytometry to determine
that cyclosporine alters the platelet plasma membrane which results in increased
expression of phosphatidylserine.52 In another study comparing renal transplant patients
to hypertensive control patients, P-selectin expression increased with all
immunosuppressive agents, including cyclosporine, although platelet aggregation was not
measurably affected.87 Another study also demonstrated an increase in P-selectin
expression in renal transplant recipients treated with cyclosporine, but similarly found no
measurable increase in platelet aggregation.88 The promotion of platelet
phosphatidylserine and P-selectin will act as a catalysts for thrombin generation to
expedite platelet procoagulant activity and thrombus formation.
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Cyclosporine has also been shown to increase platelet production of thromboxane
A2 and alter cyclooxygenase expression.89-91 Several human studies have demonstrated
an increase in thromboxane production during cyclosporine administration in renal
transplant and coronary artery disease patients.92-96 When compared to renal transplant
recipients administered azathioprine, patients receiving cyclosporine had increased
thromboxane production and increased rates of thrombus formation within the renal
parenchyma.93 Previous studies in rats have also demonstrated that cyclosporine
suppresses COX-2 expression in a number of different tissues.91,97
The following manuscript consists of three separate studies that evaluated platelet
function and cyclooxygenase expression during aspirin and cyclosporine administration.
The initial study, using high or anti-inflammatory doses of aspirin, utilized flow
cytometry to identify and quantify relative COX-1 and COX-2 expression in circulating
canine platelets, and to investigate the effects of aspirin on platelet expression of both
COX isoforms. The second study, using low doses of aspirin, utilized similar
methodology, but tried to determine if low dose aspirin therapy would consistently affect
platelet function and thromboxane production and, if not, whether pre-existing COX
isoform expression or subsequent changes in isoform expression were associated with
aspirin resistance. The final study was designed to thoroughly evaluate the effects of
cyclosporine on hemostasis in normal dogs, concentrating on platelet function,
thromboxane production and expression of P-selectin, phosphatidylserine, COX-1 and
COX-2, and thereby ascertain whether treatment with cyclosporine could feasibly put
canine IMHA patients at an increased risk of thromboembolic complications.
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CHAPTER II
PLATELET CYCLOOXYGENASE EXPRESSION IN NORMAL DOGS
Introduction
The cyclooxygenase (COX) enzyme plays a key role in normal platelet function.
Platelet COX activity is required to convert arachidonic acid to prostaglandin H2, leading
to the production of several biologically active prostaglandins, including thromboxane
A2.1,2 Thromboxane A2 is a potent vasoconstrictor and platelet activator, and production
of thromboxane A2 by platelets is essential for normal platelet function.
At least three COX isoforms have been described in dogs. COX-1 is
constitutively expressed in most body systems, and functions to maintain normal cellular
activities including platelet thromboxane A2 production, maintenance of gastric mucosal
protection, and preservation of renal blood flow.2,3 The COX-3 isoform is transcribed
from the COX-1 gene as a splice variant and has similar catalytic features, but only about
20% of the activity of COX-1.4,5 Relative to COX-1, COX-2 has a far more limited
tissue distribution, and expression is often at much lower levels. COX-2 expression
occurs in the brain, kidney, thymus and the vascular endothelium.2,6-8 COX-2 is also
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present in circulating monocytes, tissue macrophages and fibroblasts.2,8 COX-2
expression can be induced by various endogenous and exogenous mediators including
inflammatory cytokines, growth factors, and endotoxins.2,3,9 Induction of COX-2 occurs
primarily at the post-transcriptional level.10
Because mature platelets do not contain a nucleus and are therefore incapable of
mRNA synthesis, and because COX-1 is usually constitutively expressed by cells
whereas COX-2 expression is more typically induced, it was long believed that COX-1
was the only COX isoform expressed in circulating platelets, and that COX induction
could happen only at the level of the bone marrow. As a result, it was also believed that
COX-1 was the primary mediator of platelet thromboxane A2 production.7,11-13 Recently,
however, a flow cytometry technique has been described that has identified and
quantified the expression of both COX-1 and COX-2 in some mature circulating human
platelets.11 The COX-2 isoform has also been identified in higher numbers of young
(reticulated) platelets.1,6,14 These recent discoveries suggest that COX-2 could in fact
play a role in platelet function.8,11 To our knowledge, COX-2 has not previously been
identified in circulating canine platelets.
Aspirin (acetylsalicylic acid) is one of the most commonly administered antiplatelet medications in both human and veterinary medicine. Aspirin binds to and
irreversibly acetylates serine residues in the active sites of the COX-1 and COX-2
enzymes, resulting in decreased platelet thromboxane A2 production and inhibition of
platelet function.1,15-20
The main objective of our study was to utilize flow cytometry to identify and
quantify relative COX-1 and COX-2 expression in circulating canine platelets. To
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further investigate the respective roles of the COX isoforms, our study also evaluated the
effects of aspirin on platelet expression of both isoforms. Platelet function analysis and
measurement of urinary 11-dehydro-thromboxane B2 (11-dTXB2) were also employed to
explore the relationships between COX isoform expression, thromboxane production and
platelet function in aspirin-treated dogs.

Material and Methods

Study Design
Eight healthy female intact Walker hound dogs were used in the study. The dogs
were not exposed to any drugs or vaccines for at least two months prior to study
commencement. Aspirina was administered to each dog at a standard anti-inflammatory
dose of 10 mg/kg PO every 12 hours for 10 days. The administered aspirin dose was
10.62 ± 0.610 (mean, SD) mg/kg, PO, every 12 hours. All dogs completed the study.
Blood was collected for flow cytometric measurement of platelet COX expression prior
to the first aspirin dose, 1 to 4 hours after aspirin administration on Day 10, and 14 days
after the last dose of aspirin (washout). Blood and urine were collected for PFA-100®
testing and urinary 11-dTXB2 analysis at two time points, prior to the first aspirin dose
and 1 to 4 hours after aspirin administration on Day 10.

Animals
The mean age of the dogs was 5 years (range, 1-6 years). Individual dog weights
ranged from 20.5 to 24.2 kg (median, 22.3 kg). Body weight was obtained at the
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beginning of the study and used to calculate all subsequent dosing. Normal health status
was established based on the normal results of physical examination, buccal mucosal
bleeding time, complete blood count (including manual platelet count), serum
biochemistry, urinalysis, prothrombin time, partial thromboplastin time, von Willebrand
factor antigen testing (ELISA method), heartworm testing, and rickettsial and Babesia
serology. Animal use was approved by the Mississippi State University Institutional
Animal Care and Use Committee.

Flow Cytometric Analysis of Platelet COX-1 and COX-2 Expression
Blood was collected via jugular venipuncture with a 20 gauge needle into a glass
vacutainer tube containing 3.8% sodium citrate.b Sample preparation for flow cytometry
was initiated within 1 hour of collection.
COX-1 labeling: A modification of a previously described protocol for quantitating
COX-1 expression on human platelets was used to label COX-1.11 Briefly, 5 µL of
citrated whole blood was added to 45 µL of FACS-PBS and incubated for 30 minutes
with 10 µL of FITC-conjugated monoclonal mouse anti-ovine-COX-1 antibody.c Five
microliters of IgG2b-FITC isotype controld was run in parallel with each set of samples.
The samples were then incubated for 30 minutes with 3 µL of monoclonal antibody
mouse anti-human CD9:RPE antibodye to label platelets. Samples were fixed for 10
minutes at 4oC in the dark with 1% paraformaldehyde.f
COX-2 labeling: A modification of a previously described protocol for quantitating
COX-2 expression in permeabilized human platelets was used to label COX-2.11 Briefly,
5 µL of citrated whole blood was added to 45 µL of FACS-PBS and fixed at 4oC in the
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dark for 10 minutes with 1% paraformaldehyde. Samples were washed with PBS and
pelleted by centrifugation (400 g for 7 minutes). The supernatant was discarded, and the
pellet was resuspended and incubated in 0.3% Triton X-100g for 10 minutes, and the
wash step was repeated. The samples were then incubated at room temperature in the
dark for 30 minutes with 15 µL of a monoclonal FITC-conjugated mouse anti-humanCOX-2 antibody.h Platelets were labeled by adding 20 µL of monoclonal mouse anti-pig
CD61-purified antibodyi and incubated for 30 minutes, followed by the addition of 100
µL of goat anti-mouse IgG:RPE antibodyj and incubated for 30 minutes. A FITC-IgG1
isotype controlk was run in parallel with all samples.
After labeling of platelets, samples were stored in the dark at 4oC until analysis.
Flow cytometric analysis was performed within 2 hours of sample preparation. Platelets
were analyzed using a flow cytometerl at a wavelength of 488 nanometers with CellQuest
Pro software.m Platelet populations were displayed on log forward-scatter versus log
side-scatter plots. Compensation was performed to compensate for spectral overlap of
two different fluorochromes, FITC and PE. Gates were adjusted to baseline platelet
populations. A total of 5,000 gated events were recorded for both COX isoforms. COX
expression was quantified by the intensity of antibody staining and was expressed as
mean fluorescence intensity (MFI). Fluorescence from the isotype control was subtracted
from each sample. A histogram was created with MFI on the x-axis and number of
events on the y-axis.
All of the antibodies used in this study were cross reactive with canine antigens,
according to the manufacturers. Previous studies have demonstrated that all of the
critical catalytic residues found in ovine COX-1 are also found in the canine COX33

1molecule, and that there is a greater than 90% sequence similarity between the human
and canine COX-2 molecule.21 Furthermore, anti-ovine and anti-human antibodies have
been used previously for identification of canine COX-1 and COX-2, respectively.21 In
pilot studies in our laboratory prior to initiation of this study, the expression of both COX
isoforms was analyzed in canine platelets via flow cytometry with both platelet rich
plasma and whole blood samples, and samples were also analyzed with several antibodies
(anti-CD9, anti-CD61, and anti-CD62P) known to be expressed on the surface of
platelets. The sample type and antibody which provided the most consistent
identification (isotype controls IgG2b:PE, IgG1:PE, IgG1:PE, respectively) of the platelet
population for each isoform assay was then used in the study.

Platelet Function Analysis
Platelet function was analyzed using a commercial point-of-care platelet function
analyzer (PFA-100®)n. The PFA-100® has been previously evaluated for use in dogs, and
the instrument was used according to manufacturer’s instructions.22-24 Briefly, the PFA100® is an in vitro platelet function analyzer that measures the time needed to form a
platelet plug in an environment similar to blood vessels. Platelet agonists such as
collagen and epinephrine are used to activate platelets under high shear conditions. The
time taken for the activated platelets to form a plug and occlude an aperture designed to
replicate damaged vascular endothelium is measured and reported as the closure time.
The instrument cut-off time for non-closure of the aperture is greater than 300 seconds.
Blood samples were collected into 5 ml blood collection vacutainer tubes
containing 3.8% sodium citrate, and samples were kept at room temperature until
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analysis. An automated hematologic analyzero was used to establish a platelet count and
hematocrit for each sample prior to PFA-100® analysis. All samples were analyzed
within two hours of collection. Samples were mixed well prior to analysis, and 800 μL of
citrated whole blood sample were transferred into a PFA-100® cartridge containing the
agonists collagen and epinephrine (collagen/EPI cartridge)p, and analyzed. Cartridges
were stored at 4oC and warmed to room temperature before analysis.

Urinary 11-Dehydro-Thromboxane B2 Analysis
Urinary 11-dTXB2 concentration was measured using a multiplex analyzerq
(which utilizes xMAP technology with fluorescently dyed microspheres to detect low
concentrations of substrates) and a commercial competitive enzyme immunoassay kitr
that has been previously validated in the dog.25 Urine was collected via cystocentesis,
batched, and stored at -80oC until analysis. Prior to analysis, the urine was thawed and the
specific gravity was measured. The assay buffer was used to standardize the samples to a
urine specific gravity range optimized for the analyzer working range (1.003 to 1.012).
All samples were analyzed in duplicate according to the manufacturer’s instructions, and
reported in picograms per milliliter of urine. A correction factor was applied to account
for the sample dilutions. Briefly, a 96-well plate was prepared by adding 100 µl of the
diluted sample to the appropriate well, followed by the addition of 50 µl of both 11dTXB2 Phycoerythrin Tracer and 11-dTXB2 beads to each well. The plate was placed on
an orbital shaker and incubated in the dark at room temperature for 4 hours prior to
analysis.
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A biochemistry analyzers was used to measure urine creatinine concentration by
the Jaffe Reaction. Urine 11-dTXB2 concentration was normalized to the individual’s
urine creatinine by determining the 11-dTXB2 to creatinine ratio, as previously
described.25,26

Statistical Analysis
A single population, repeated measures design was utilized in this study. After
visual assessment of Q-Q plots, COX-1 and COX-2 expression, and 11-dTXB2
concentration were deemed to be approximately normally distributed, although the
maximal assay closure time was reached at some time points thus affecting normal
distribution for the PFA-100 results. Results of platelet COX expression and urine 11dTBX2 concentration in dogs treated with aspirin were individually assessed by analysis
of variance (ANOVA) using the MIXED procedure in SAS for Windows version 9.2t.
Sample time was included in the model as a fixed effect. The repeated measures of dogs
over time were accounted for by REPEATED statements assuming an unstructured
covariance structure. Differences in least square means with Tukey-Kramer adjustment
of p-values were used for multiple comparisons of the three time points for the COX-1
and COX-2 analyses. To accommodate the non-normal distribution of the PFA-100®
results, differences in baseline and Day 10 levels were evaluated by a Wilcoxon Signed
Rank Test using the UNIVARIATE procedure in SAS for Windows version 9.2. A pvalue of less than 0.05 was considered to be significant for all analyses.
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Results

Flow Cytometric Analysis of Platelet COX-1 and COX-2 Expression
Platelet COX-1 expression was measurable in all dogs prior to drug
administration. Time was found to be a significant factor within the model (p=0.003).
There was a significant increase (p=0.003) in COX-1 expression from baseline values by
Day 10 of aspirin administration (Figure 2.1), on average by 250%, with a range of 63476%. By the end of the washout period, there was a significant decrease (p=0.002) in
COX-1 expression from Day 10 values (Figure 2.1). There was no significant difference
between baseline and washout values (p=0.140). The aspirin-associated increase in
COX-1 expression followed by the decrease after drug discontinuation was observed in
all dogs.
Platelet COX-2 expression was also measurable in all dogs prior to drug
administration. Time was found to be a significant factor within the model (p=0.031).
There was no significant change in COX-2 expression from baseline values following
administration of aspirin (p=0.124) (Figure 2.2). By the end of the washout period,
however, there was a significant increase (p=0.026) in COX-2 expression from Day 10
values. There was no significant difference between baseline and washout values
(p=0.782). Individual dog responses were variable: COX-2 expression decreased during
aspirin administration in 6 dogs (average decrease 70%, range 56-80%), and increased in
2 dogs (by 8% and 116%).
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Figure 2.1

Mean COX-1 expression for 8 dogs after treatment with aspirin (10 mg/kg
PO every 12 hours for 10 days). There was a significant (p=0.003)
increase in COX-1 expression from baseline values after administration of
aspirin (*), followed by a significant (p=0.002) decrease from Day 10
values after the discontinuation of aspirin (**). There was no difference
(p=0.140) between baseline and washout time points.
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Figure 2.2

Mean COX-2 expression for 8 dogs after treatment with aspirin. Although
there was a decrease in expression from baseline values after
administration of aspirin, this decrease was not significant (p=0.124).
There was a significant (p=0.026) increase from Day 10 values after the
discontinuation of aspirin (**). There was no difference (p=0.782)
between baseline and washout time points.
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Platelet Function Analysis
The mean baseline PFA-100® closure time was 167 seconds (range 84-242
seconds). There was a significant (p<0.008) increase in closure time by Day 10 of aspirin
administration on average by 75%, mean closure time was 294 seconds (range 274 – 300
seconds), although the increase was in all likelihood of a greater magnitude since 6 out of
8 dogs attained the maximum reportable closure time of 300 seconds. Increased closure
times were seen in all dogs (Figure 2.3).

Figure 2.3

PFA-100® closure times in individual dogs after treatment with aspirin.
Closure times were prolonged in all 8 dogs. Maximum reportable closure
time is 300 seconds. Lines were added between data points to better
demonstrate variation among dogs.
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Urinary 11-Dehydro-Thromboxane B2 Analysis
The mean baseline urinary 11-dTXB2 to creatinine ratio was 23.7 (range 9.042.5). By Day 10 of aspirin administration, there was a significant (p=0.014) decrease in
urinary 11-dTXB2 to creatinine ratio to a mean ratio of 8.5 (range 4.7-12.7), an average
decrease of 64%. A decrease in urinary 11-dTXB2 to creatinine ratio was seen in all dogs
(Figure 2.4).

Figure 2.4

Urinary 11-dTXB2 to creatinine ratios in individual dogs after treatment
with aspirin. Urinary 11-dTXB2 to creatinine ratios decreased in all 8
dogs. Lines were added between data points to better demonstrate
variation among dogs.
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Discussion
This study demonstrates COX-2 expression in circulating canine platelets.
Previously published studies were often unable to detect COX-2 expression in circulating
human and canine platelets.7,11,13 As in recently published human platelet studies,
addition of a permeabilization step prior to flow cytometry enabled us to detect COX-2
expression within the platelets of all of the dogs in our study. The functions of the COX2 isoform in canine platelets are currently unknown.
Our study revealed that exposure to anti-inflammatory doses of aspirin altered
canine platelet expression of both COX-1 and COX-2. Mature platelets are anucleate and
would therefore not be expected to be capable of de novo changes in expression of
proteins such as COX-1 or COX-2 in response to endogenous or exogenous stimuli.
Nucleated marrow platelet precursor cells such as megakaryocytes contain COX-1 and
COX-2,8,14 and changes in COX expression that are induced at the level of these platelet
precursors would be expected to result in similar changes in platelets derived from
affected megakaryocytes. Young newly released platelets also contain residual mRNA
derived from precursor megakaryocytes,27,28 and retain the intracellular molecular
mechanisms necessary for protein production. In fact, in many tissues, COX induction is
thought to occur at the post-transcriptional level. Therefore, it is possible that some of
the aspirin-induced changes in platelet COX expression that occurred in our study
occurred in circulating platelets. Since our study measured COX expression only once
during aspirin therapy, 10 days after the drug was commenced, we cannot determine at
what time point altered COX expression became apparent in platelets, and thus cannot
determine where COX induction occurred. Additional studies evaluating platelet COX
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expression at several time points during the first week of aspirin therapy, and using flow
cytometry to measure COX expression in immature ‘reticulated’ platelets, will help to
more precisely determine the sequential effects of aspirin on COX expression at the level
of the megakaryocyte, the immature platelet, and the mature circulating platelet.
Our study demonstrated a significant increase in platelet COX-1 expression after
aspirin administration. While it is generally believed that COX-1 is constitutively
expressed in most tissues, up-regulation of COX-1 expression has been demonstrated in
human megakaryoblasts during thrombocytopoiesis, although the mechanism of enzyme
up-regulation is not fully understood.29,30 Up-regulation of COX-1 expression has also
been identified in equine jejunal mucosa following periods of ischemia, in human gastric
mucosa in association with gastric ulcers, and in humans experiencing rejection of a renal
allograft.31-35 Certainly it appears that in some circumstances, cellular COX-1 expression
is induced rather than constitutive, and our study provides supportive evidence that
suggests that exposure to aspirin induces COX-1 expression by platelets or platelet
precursors in dogs, although the mechanism for this induction remains unknown.
Although platelet COX-1 expression was increased, platelet function was concurrently
decreased as evidenced by prolonged PFA-100® closure times and decreased urinary 11dTXB2 levels. Prolongation of PFA-100® closure time using the collagen/EPI cartridge
is considered to be a sensitive indicator of aspirin-induced platelet dysfunction.23
Thromboxane B2 is a metabolite of platelet-derived thromboxane A2, and measurement of
urinary thromboxane B2 metabolites such as 11-dTXB2 is also considered to be a
sensitive indicator of aspirin-induced inhibition of platelet cyclooxygenase activity and
resultant decreased thromboxane A2 production.36-38 Taken together, the increased PFA43

100® closure times and decreased urinary 11-dTXB2 levels seen in the dogs in our study
provide strong supportive evidence of aspirin-induced inhibition of platelet COX activity,
a finding that is to be expected given the relatively high doses of aspirin used. The
increase in platelet COX-1 expression with a significant decrease in urinary 11-dTXB2
concentrations could signify a negative feedback control to compensate for decreased
COX-1 function.
Our study also revealed that, in contrast to COX-1, platelet COX-2 expression did
not significantly change during the period of aspirin administration. By the end of the
post-aspirin washout period, however, there was a significant increase in COX-2
expression compared to Day 10 values, suggesting that aspirin does have an effect on
platelet COX-2 expression. Further studies with a larger number of dogs will be needed
to determine the true nature of aspirin’s effect on canine platelet COX-2 expression.
Previously described flow cytometry techniques for measuring platelet COX-2
have utilized platelet-rich plasma in order to minimize any potential interference
associated with whole blood cellular components.11 The extra platelet handling
associated with the creation of platelet-rich plasma, however, has the potential to activate
platelets and thereby artifactually alter test results. Prior to the initiation of this study, we
conducted a preliminary experiment comparing the use of platelet-rich plasma and whole
blood for analysis of platelet COX-1 and COX-2 expression via flow cytometry, and
found similar results with both methodologies. We therefore elected to use whole blood
for this study as the use of whole blood was less time-consuming and not as likely to lead
to platelet activation artifacts.
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Recently, a COX-2 splice variant was identified from platelet mRNA that appears
to be induced by coronary artery bypass grafting in people, with a 200-fold increase in
this variant after surgery. The role of this ‘COX-2a’ splice variant in platelet function is
unclear, although it does not appear to be involved in thromboxane synthesis. In patients
undergoing coronary artery bypass grafting, COX-1 mRNA is the predominant platelet
COX isoform, with minimal COX-2 mRNA expression before surgery. Post-operatively,
however, there is marked variability in COX expression, with induction of COX-2a
mRNA accounting for more than half of the total COX mRNA in some patients.39
Interestingly, those patients that expressed the COX-2a splice variant were also aspirin
resistant following surgery. The human COX-2a splice variant is COX-2
immunoreactive, and it is possible that similar immunoreactive splice variants occur in
the dog, and that at least some of the platelet COX-2 detected in our study consisted of
splice variants. Our study, however, was performed in healthy dogs, therefore it is
unlikely that induction of COX-2a splice variants would have occurred. Further studies
are needed to identify possible splice variants in dogs and to determine the role of COX-2
and its variants in platelet function.
Some human patients do develop thromboembolic complications despite
prophylactic treatment with standard anti-platelet ‘low-dose’ aspirin. This treatment
failure has been termed ‘aspirin resistance’. Although the exact incidence of aspirin
resistance in people is undetermined, an estimated 8-45% of patients appear to be poorly
responsive to aspirin therapy.15,20,40,41 The mechanism of aspirin resistance is currently
unknown, but it is likely that the etiology is multifactorial. Platelet COX-2, by providing
an alternative pathway to COX-1 for platelet thromboxane A2 synthesis, has been
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proposed as one potentially important cause of human aspirin resistance.20 Although
low-dose aspirin has been shown to produce marked suppression of COX-1 activity in
most people, clinical studies have revealed that approximately 20% of patients receiving
aspirin have incomplete suppression of urine thromboxane metabolites, suggesting the
presence of an alternative pathway (such as COX-2) for thromboxane A2 synthesis.42 In
conditions associated with high rates of platelet turnover and increased thrombopoiesis
such as immune-mediated thrombocytopenia and recovery from stem cell transplantation,
younger platelets have greater COX-2 expression than mature platelets.8,43 One recent
study found that while only a small portion (about 10%) of circulating human platelets
typically express the COX-2 isoform, up to 60% of all circulating platelets will express
COX-2 during conditions of increased platelet turnover and regeneration.1,8 Additional
studies are required to determine whether COX-2 plays a direct role in resistance to low
dose aspirin.
Since all of our dogs responded to relatively high anti-inflammatory doses of
aspirin by exhibiting significant platelet dysfunction, as demonstrated by prolonged PFA100® closure times and decreased urinary thromboxane B2 concentrations, our study
revealed no evidence of aspirin resistance. However, since aspirin resistance is typically
only considered to be a problem in patients receiving aspirin at lower ‘anti-platelet’
doses, the findings of our study are not surprising. The dose used in this study was much
greater than the dose typically used for thromboprophylaxis in dogs. Additional studies
are required to determine whether dogs respond in the same manner to anti-platelet doses
of aspirin using a typical low-dose regimen of 0.5 to 1.0 mg/kg PO Q24 hours,44 or
whether aspirin resistance will become apparent at lower drug doses. However, even at
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the high aspirin doses used in our study, platelet COX-2 expression in response to drug
treatment appeared to vary markedly between individual dogs. Studies designed to
evaluate platelet COX-1 and COX-2 expression and concurrently measure platelet
function and thromboxane A2 synthesis in dogs receiving low-dose aspirin may enable us
to determine whether the variable individual dog COX-2 responses to aspirin at high drug
doses correlate with aspirin resistance at lower drug doses.
Aspirin is commonly administered to dogs, both for its anti-inflammatory
properties and for its anti-platelet effects in patients at risk for thromboembolic
complications. Our results demonstrate that circulating canine platelets express both
COX-1 and COX-2. Additional research is required to better delineate the functions of
platelet-derived COX-2 and its potential role in aspirin responsiveness in both normal and
clinically ill dogs.

Materials, Instruments, and Supplies
a. Aspirin, Major Pharmaceuticals, Livonia, MI
b. 3.8% sodium citrate, Vacutainer tube, Becton Dickinson, Franklin Lakes, NJ
c. FITC-conjugated monoclonal COX-1, Clone CX111, Cayman Chemical Co, Ann
Arbor, MI
d. FITC-conjugated IgG2b isotype control, Santa Cruz Biotechnology, Inc, Santa Cruz,CA
e. Monoclonal anti-human CD9:RPE, Clone MM2/57, AbD Serotec, Raleigh, NC
f. Paraformaldehyde, Biolegend Inc., San Diego, CA
g. Triton X-100, Sigma-Aldrich, St. Louis, MO
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h. FITC-conjugated monoclonal COX-2, Clone CX299, Cayman Chemical Co, Ann
Arbor, MI
i. Monoclonal CD61-purified, Clone JM2E5, Accurate Chemical, Westbury, NY
j. Goat anti-mouse IgG:RPE, AbD Serotec, Raleigh, NC
k. FITC-conjugated IgG1 isotype control, Santa Cruz Biotechnology, Inc., Santa Cruz,CA
l. FACSCalibur, Becton Dickinson, San Jose, CA
m. CellQuest software, Becton Dickinson, San Jose, CA
n. PFA-100®, Siemens Healthcare Diagnostics, Deerfield, IL
o. Abbott Cell-Dyn® 3700, Abbott Laboratories, Abbott Park, IL
p. PFA Collagen/EPI Test Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
q. Luminex® 200 System xMAP Technology, Luminex Corporation, Austin, TX
r. Luminex® 11-dehydro Thromboxane B2 Kit, Cayman Chemical Co, Ann Arbor, MI
s. ACE Alera® Clinical Chemistry System, Alfa Wasserman, Inc., West Caldwell, NJ
t. SAS for Windows version 9.2, SAS Institute, Cary, NC, 2008

48

References Cited
1. Guthikonda S, Lev E, Patel R, et al. Reticulated platelets and uninhibited COX-1 and
COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490 –
496.
2. Rocca B, FitzGerald G. Cyclooxygenase and prostaglandins: shaping up the immune
response. Int Immunopharmacol 2002; 2: 603 – 630.
3. Bjorkman D. The effect of aspirin and nonsteroidal anti-inflammatory drugs on
prostaglandins. Am J Med 1998; 105 (1B): 8S – 12S.
4. Munoz J, Navarro C, Noriega V, et al. Synergism between COX-3 inhibitors in two
animal models of pain. Inflammopharmacol 2010; 18: 65 – 71.
5. Simmons D. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res
2003; 110: 265 – 268.
6. Tanaka N, Sato T, Fujita H, et al. Constitutive expression and involvement of
cyclooxygenase-2 in human megakaryocytopoiesis. Arterioscler Thromb Vasc Biol
2004; 24: 607 – 612.
7. Kay-Mugford P, Benn S, LaMarre J, et al. Cyclooxygenase expression in canine
platelets and Mardin-Darby canine kidney cells. Am J Vet Res 2000; 61: 1512 – 1516.
8. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced
during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl
Acad Sci USA 2002; 99: 7634 – 7639.
9. Bergh M, Budsberg S. The Coxib NSAIDs: Potential clinical and pharmacologic
importance in veterinary medicine. J Vet Intern Med 2005; 19: 633 – 643.
10. Dixon D, Kaplan C, McIntyre T, et al. Post-transcriptional control of
cyclooxygenase-2 gene expression. J Biol Chem 2000; 275: 11750 – 11757.
11. Weber A, Przytulski B, Schumacher M, et al. Flow cytometry analysis of platelet
cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients
undergoing coronary artery bypass grafting. Br J Haematol 2002; 117: 424 – 426.
12. Ueno N, Murakami M, Tanioka T, et al. Coupling between cyclooxygenase, terminal
prostanoid synthase, and phospholipase A2. J Biol Chem 2001; 276: 34918 – 34927.
13. Yu Y, Cheng Y, Fan J, et al. Differential impact of prostaglandin H synthase 1
knockdown on platelets and parturition. J Clin Invest 2005; 115: 986 – 995.
49

14. Zetterberg E, Lundberg L, Palmblad J. Expression of cox-2, tie-2 and glycodelin by
megakaryocytes in patients with chronic myeloid leukaemia and polycythaemia vera. Br
J Haematol 2003; 121: 497 - 499.
15. Patrono C, Dalen J, Fuster V, et al. Platelet-Active Drugs. Chest 2001; 119: 39S –
63S.
16. Mroske C, Plant M, Franks D, et al. Characterization of prostaglandin endoperoxide
H synthase-1 enzyme expression during differentiation of the megakaryocytic cell line
MEG-01. Exp Hematol 2000; 28: 411 – 421.
17. Alagha A, Moman E, Adamo M, et al. Design, synthesis and evaluation of aspirin
analogues having an additional carboxylate substituent for antithrombotic activity.
Bioorg Med Chem Lett 2009; 19: 4213 – 4216.
18. Assadian A, Lax J, Meixner-Loicht U, et al. Aspirin resistance among long-term
aspirin users after carotid endarterectomy and controls: Flow cytometric measurement of
aspirin-induced platelet inhibition. J Vasc Surg 2007; 45: 1142 – 1147.
19. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a
comprehensive systemic review. Br J Clin Pharmacol 2008; 66: 222 – 232.
20. Kour D, Tandon V, Kapoor B, et al. Aspirin Resistance. New Horiz 2006; 8: 116 –
117.
21. Wilson J, Chandrasekharan N, Westover K, et al. Determination of expression of
cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to
nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004; 65 (6): 810 – 818.
22. Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, von
Willebrand’s Disease, coagulopathies, and haematocrit on results obtained using a
platelet function analyser in dogs. Vet J 2003; 165: 43 – 52.
23. Nielsen L, Zois N, Pedersen H, et al. Platelet function in dogs: breed differences and
effect of acetylsalicylic acid administration. Vet Clin Pathol 2007; 36: 267 – 273.
24. Morales F, Couto C, Iazbik M. Effects of 2 concentrations of sodium citrate on
coagulation test results, von Willebrand Factor concentration, and platelet function in
dogs. J Vet Intern Med 2007; 21: 472 – 475.
25. Baltzer W, McMichael M, Ruaux C, et al. Measurement of urinary 11-dehydrothromboxane B2 excretion in dogs with gastric dilatation-volvulus. Am J Vet Res 2006;
67: 78 – 83.

50

26. McConnell J, Cheryk L, Durocher A, et al. Urinary 11-dehydro-thromboxane B2 and
coagulation activation markers measured within 24 h of human acute ischemic stroke.
Neurosci Lett 2001; 313: 88 – 92.
27. Booyse FM, Rafelson ME Jr. Stable messenger RNA in the synthesis of contractile
protein in human platelets. Biochim Biophys Acta 1967; 145: 188 – 190.
28. Brogren H, Karlsson L, Anderson M, et al. Platelets synthesize large amounts of
active plasminogen activator inhibitor 1. Blood 2004; 104 (13): 3943 – 3948.
29. Ueda N, Yamashita R, Yamamoto S, et al. Induction of cyclooxygenase-1 in a
human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochimica et
Biophysica Acta 1997; 1344: 103-110.
30. DeLong C, Smith W. An intronic enhancer regulates cyclooxygenase-1 gene
expression. Biochem Biophys Res Commun 2005; 338: 53-61.
31. Tomlinson J, Wilder O, Young K, et al. Effects of flunixin meglumine or etodolac
treatment on mucosal recovery of equine jejunum after ischemia. Am J Vet Res 2004; 65:
761 – 769.
32. Bhandari P, Bateman A, Mehta R, et al. Mucosal expression of cyclooxygenase
isoforms 1 and 2 is increased with worsening damage to the gastric mucosa.
Histopathology 2005;46:280-286.
33. Hoffmann U, Banas B, Kruger B, et al. Expression of cyclooxygenase-1 and
cyclooxygenase-2 in human renal allograft rejection – a prospective study. Transpl Int
2006; 19: 203-212.
34. Dore M, Cote L, Mitchell A, et al. Expression of prostaglandin G/H synthase type 1,
but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem 1998; 46 (1):
77-84.
35. Gupta R, Tejada L, Tong B, et al. Cyclooxygenase-1 is overexpressed and promotes
angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63: 906-911.
36. Jones CJ, Budsberg SC. Physiologic characteristics and clinical importance of the
cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000;217:721-729.
37. Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo:
implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
38. Perneby C, Granstrom E, Beck O, et al. Optimization of an enzyme immunoassay for
11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. Thromb Res
1999;96:427-436.
51

39. Censarek P, Steger G, Paolini C. Alternative splicing of platelet cyclooxygenase-2
mRNA in patients after coronary artery bypass grafting. Thromb Haemost 2007; 98:
1309 – 1315.
40. Martin C, Talbert R. Aspirin Resistance: An evaluation of current evidence and
measurement methods. Pharmacotherapy 2005; 25: 942 – 953.
41. Frelinger A, Furman M, Linden M, et al. Residual arachidonic acid-induced platelet
activation via an adenosine diphosphate-dependent but cyclooxygenase-1 – and
cyclooxygenase-2-independent pathway: A 700-Patient study of aspirin resistance.
Circulation 2006; 113:2888-2896.
42. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and
spontaneous myocardial ischemia in unstable angina. Thromb Haemost 1990; 63(2):163168.
43. Zimmerman G, Weyrich A. Signal-dependent protein synthesis by activated platelets
new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008;
28: s17 – s24.
44. Weinkle T, Center S, Randolph J, et al. Evaluation of prognostic factors, survival
rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases
(1993 – 2002). J Am Vet Med Assoc 2005; 226:1869 – 1880.

52

CHAPTER III
CYCLOOXYGENASE EXPRESSION AND PLATELET FUNCTION IN NORMAL
DOGS RECEIVING LOW DOSE ASPIRIN
Introduction
Thromboembolic complications in dogs are associated with multiple diseases,
including immune-mediated hemolytic anemia (IMHA), protein-losing nephropathies,
and hyperadrenocorticism.1,2 Anti-platelet therapy plays an important role in the
prevention of thromboembolic complications. One of the most commonly used antiplatelet medications, aspirin, is highly effective at inhibiting both human and canine
platelet function.3-7 Anti-inflammatory doses of aspirin will inhibit platelet function,
decrease inflammation, and provide analgesia, but can cause significant side effects.8
Lower doses of aspirin, in contrast, will maintain the anti-platelet properties of the
medication without the side effects, making low dose aspirin an appealing treatment for
the prevention of thromboembolic complications. The administration of low doses of
aspirin has been associated with an improved survival rate in dogs with IMHA.9

This chapter has been submitted for publication to the Journal of Veterinary
Internal Medicine. Dudley, A, Thomason J, Fritz S, Grady J, Stokes J, Wills R, Pinchuk
L, Mackin A, Lunsford K. Cyclooxygenase Expression and Platelet Function in Normal
Dogs Receiving Low Dose Aspirin. John Thomason is the corresponding author for this
article.
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Unfortunately, despite preventative therapy, some dogs treated with aspirin will
continue to develop thromboembolic complications. A similar phenomenon occurs in
humans that are receiving low doses of aspirin, indicating that these patients are poorly
responsive to the anti-platelet effects of aspirin (‘aspirin resistant’). The true incidence of
aspirin resistance in humans is unknown, but the published incidence ranges from 8-45%
of human patients.3,10-12 Since canine clinic patients appear to inconsistently respond to
low dose aspirin, it is possible that, similar to humans, dogs also experience aspirin
resistance. The true incidence of aspirin resistance in dogs is, however, unknown. The
exact mechanism for aspirin resistance in both humans and dogs is also unknown, but
possible explanations include genetic and acquired differences in cyclooxygenase (COX)
enzyme activity or thromboxane receptors, increased platelet reactivity to other platelet
agonists, and alternative pathways of thromboxane generation.10
Once synthesized and released by activated platelets, thromboxane A2 (TXA2)
triggers vasoconstriction, enhances platelet aggregation, and induces further platelet
activation.5,13 The COX enzyme, which exists in two major isoforms, COX-1 and COX2, is primarily responsible for platelet generation of thromboxane A2.14,15 Previously,
circulating platelets were thought to contain only the COX-1 isoform,16-18 but recent
studies have identified the COX-2 isoform in both human and canine platelets.15,17,19 The
COX-1 isoform was originally believed to be the sole source of platelet TXA2
production,16 but platelet COX-2 could provide an alternate source of TXA2 production,
offering a possible mechanism for aspirin resistance.
Aspirin functions as a permanent inhibitor of the COX enzyme via acetylation of
a serine residue.10,20,21 Permanent inhibition of the COX enzyme prevents conversion of
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arachidonic acid to prostaglandin H2 and many subsequent prostaglandins, including
TXA2 and prostacyclin. While platelet-derived TXA2 plays a critical role in
vasoconstriction and promoting platelet aggregation, prostacyclin originating from the
vascular endothelium has the opposite effect by causing vasodilation and inhibiting
platelet aggregation. Low dose aspirin, unlike higher anti-inflammatory doses, will alter
platelet function without permanently inhibiting COX function in the vascular
endothelium, allowing prostacyclin production to continue and contribute to the
prevention of thrombus formation.5
Previous studies in dogs have demonstrated that high aspirin doses consistently
inhibit platelet function6,7,19 and thromboxane production,19,22 while concurrently altering
platelet COX-1 and COX-2 expression.19 Platelet COX enzyme expression in dogs
receiving low dose aspirin has not been previously evaluated, but variations in COX
isoform expression could provide an explanation for aspirin resistance. A better
understanding of the relationship between platelet COX isoform expression and response
to low doses of aspirin could potentially allow clinicians to predict which individuals will
demonstrate aspirin resistance.
The objective of this study was to evaluate the effects of a recommended low dose
of aspirin (1 mg/kg/day)a,8 on platelet function and COX expression in healthy dogs. The
goals of our study were to determine whether low dose aspirin therapy would consistently
affect platelet function and thromboxane production, and if not, whether pre-existing
COX isoform expression or subsequent changes in isoform expression were associated
with aspirin resistance.
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Material and Methods

Study Population
Healthy client owned adult dogs were recruited from students, staff and faculty
associated with the Mississippi State University College of Veterinary Medicine. Owner
consent was obtained before initiation of the study. The dogs were not exposed to any
medications or vaccines for at least two weeks prior to initiation of the study, and no nonaspirin medications were administered during the testing period. All drug dosing was
based on the body weight obtained at the beginning of the study. Normal health status
was established via physical examination, complete blood count, serum chemistry,
urinalysis, heartworm testing and platelet function analysis using a point-of-care platelet
function analyzer, the PFA-100®b (collagen/ADP cartridgec). Dogs were excluded from
the study if they were found to have abnormal physical examination findings, abnormal
complete blood count or serum chemistry results, heartworm or tick-borne disease, or
platelet abnormalities based on either an abnormal platelet count or prolonged PFA-100®
(collagen/ADP) closure time. Animal use was approved by the Mississippi State
University Institutional Animal Care and Use Committee.

Study Design
Aspirind was administered orally to each dog at a dose of 1 mg/kg once daily for
10 days. Based on individual body weight, the aspirin dose was compounded by the
Mississippi State University College of Veterinary Medicine Pharmacy. Blood and urine
samples were collected from all study participants for platelet function evaluation (PFA56

100® collagen/epinephrine cartridgee), measurement of platelet cyclooxygenase
expression, and urinary thromboxane analysis on Day 0 (prior to initiating aspirin), and
again on Days 3 and 10 during aspirin administration.

Platelet Function Analysis
The PFA-100® has previously been evaluated for use in dogs6,7,23 as a commercial
point-of-care platelet function analyzer. The PFA-100® is an in vitro platelet function
analyzer that records the closure time, in seconds, needed to form a platelet plug after
activation by platelet agonists. Blood was collected via jugular venipuncture with a 20
gauge needle directly into a 5 ml vacutainer tube containing 3.8% sodium citratef.
Samples were well mixed, and 800 l of whole blood was transferred into either a
collagen/ADP cartridge (establishment of normal platelet function prior to the study) or
collagen/epinephrine cartridge (main study) for analysis. All samples were analyzed
within four hours of collection and were kept at room temperature until analysis. The
cut-off time for the instrument is greater than 300 seconds, and results were considered to
be prolonged if the closure time was greater than 300 seconds. All cartridges were stored
at 4C and warmed to room temperature before analysis.
Based on PFA-100® collagen/epinephrine closure times following aspirin
administration, all dogs were divided into one of three groups: aspirin responders
(prolonged closure times at Day 3 and 10), aspirin non-responders (no prolongation of
closure times at either time point), and inconsistent aspirin responders (prolonged closure
times on either Day 3 or 10, but not both). The initial Day 0 blood samples for platelet
function analysis (collagen/epinephrine cartridge) were discarded due to an unanticipated
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instrument malfunction. Blood samples were obtained 4 weeks after completion of
administration of aspirin to represent the baseline analysis for the PFA-100®
collagen/epinephrine cartridge.

Flow Cytometry
Blood was collected via jugular venipuncture with a 20 gauge needle directly into
a glass vacutainer tube containing 3.8% sodium citrate. Sample preparation was initiated
within 1 hour of collection.
COX-1 labeling: Platelet COX-1 expression was quantified by utilizing a
previously described protocol.19 Briefly, 5 µL of whole blood was combined with 45 µL
of FACS-PBS and incubated with a FITC-conjugated mouse anti-ovine-COX-1
monoclonal antibodyg. For platelet identification, samples were incubated with a mouse
anti-human CD9:RPE monoclonal antibodyh. Samples were fixed for 10 minutes at 4oC
in the dark with 1% paraformaldehydei.
COX-2 labeling: A previously reported protocol19 was used to quantify platelet
COX-2 expression. Briefly, 5 µL of whole blood was added to 45 uL of FACS-PBS and
fixed with 1% paraformaldehyde at 4oC in the dark. Samples were washed and then
incubated in 0.3% Triton X-100j. Following another wash, samples were incubated with
a FITC-conjugated mouse anti-human-COX-2 monoclonal antibodyk. Platelets were
identified with a mouse anti-pig CD61-purified monoclonal antibodyl and goat antimouse IgG:RPE antibodym.
Samples were stored in the dark at 4oC prior to analysis. Isotype matched
monoclonal antibodies were used for both COX antibodies. Analysis was performed
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with a flow cytometern with CellQuest Pro softwareo. Platelet populations were
displayed on log forward-scatter versus log side-angle light scatter plots. Gates were
adjusted to baseline platelet populations, and a total of 5,000 gated events were recorded
for each labeling. Expression was quantified by the intensity of antibody fluorescence
and expressed as mean fluorescence intensity (MFI). A histogram was created with MFI
on the x-axis and events on the y-axis.

Urinary 11-Dehydro-Thromboxane B2 Analysis
Urinary 11-dehydro-thomboxane B2 (11-dTXB2) was measured using a multiplex
analyzerp and a commercial competitive enzyme immunoassay kitq that has been
previously validated in the dog.24 Urine was collected either by free catch or
cystocentesis and stored at -80C until analysis. Prior to analysis, urine samples were
thawed and the specific gravity was measured. The assay buffer was used to standardize
each sample to a urine specific gravity (range, 1.002 to 1.014), which was the optimal
working range for the analyzer. Each urine sample was analyzed in duplicate and
reported in picograms per milliliter of urine. A correction factor was applied to account
for the sample dilutions. A 96-well plate was prepared by adding 100 L of the urine
sample and 50 L of both the 11-dTXB2 Phycoerythrin Tracer and the 11-dTXB2
XMAPR® beads to the appropriate well. Each plate was incubated at room temperature,
in the dark and on an orbital shaker prior to analysis. The urine creatinine concentration
of each sample was determined by a biochemistry analyzerr, and the urine 11-dTXB2
concentration was normalized to create a urinary 11-dTXB2 to creatinine ratio.24,25
59

Statistics
A power analysis was performed prior to study initiation, based on results from a
previous study evaluating the effects of non-steroidal anti-inflammatory drugs on platelet
function.26 The results of this analysis indicated that a sample size of 27 dogs would be
needed to achieve a power value of 0.80 for detection of post-aspirin changes in platelet
function. A single population, repeated measures design was utilized in this study. After
visual assessment of Q-Q plots, COX-2 expression appeared to be normally distributed;
however, COX-1, 11-dTXB2, and the PFA-100® (collagen/epinephrine) were not
considered to be normally distributed. Consequently, nonparametric methods for analysis
of repeated measures were utilized27,28 for all results. For each outcome, the data were
ranked and then analysis of variance type statistics were obtained through PROC MIXED
(SAS)s by using the ANOVAF option and the MIVQUE0 estimation method for the
covariance parameters and a REPEATED statement specifying an unstructured
covariance structure. Sample time was included in the model as a fixed effect.
Differences in least square means were used for multiple comparisons of the three time
points for the analyses; the simulation option within SAS was used for adjustment of pvalues for the pair-wise comparisons. Following classification into response groups
based on PFA-100® collagen/epinephrine closure times, the effect of responder
classification was assessed by the addition of response group and the time by response
group interaction into the COX-1, COX-2, and 11-dTXB2 models. A p-value of less than
0.05 was considered to be significant for all analyses.
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Results

Study Group Characteristics
A total of 25 dogs satisfied the inclusion criteria and participated in the study.
There were 14 different breeds with Labrador Retrievers being the most commonly
represented breed (n = 6). Other breeds included English Springer Spaniels (n = 2),
Australian Shepherds (n = 2), Shar-Pei (n = 1), Pug (n = 1), Yorkshire Terrier (n = 1),
Chesapeake Bay Retriever (n = 1), Chihuahua (n = 1), Boxer (n = 1), Border Collie (n =
1), German Shepherd (n = 1) and mixed breed dogs (n = 7). The study population
consisted of 8 neutered males, 12 spayed females, and 5 intact females. The mean age
was 3.7 years (range, 1-9 years old) and the mean body weight was 23.2 kg (range, 5.448.9 kg). One dog, a female intact Labrador Retriever, was excluded from the study after
detection of a prolonged baseline PFA-100® collagen/epinephrine closure time. The
remaining 24 dogs received aspirin for 10 days with no reported adverse effects.

Platelet Function Analysis
The mean PFA-100® collagen/epinephrine closure time on Day 0 was 140.2
seconds (range, 72-248 seconds), while the mean closure times on Days 3 and 10 were
227.3 seconds (range, 91-300 seconds) and 227.7 seconds (range, 64-300 seconds),
respectively, an increase of 62.1% from baseline values. When compared to Day 0, there
was a significant increase in closure times at both Day 3 (P < 0.001) and Day 10 (P <
0.001). There was no difference in closure times between Days 3 and 10 (P = 0.991).
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There was an equal distribution among the three groups of aspirin responsiveness, with a
total 8 dogs per group.
In the aspirin non-responder group, mean closure time on Day 0 was 122.6
seconds (range, 91-203), while the mean closure times on Days 3 and 10 were 162
seconds (range, 91–235) and 166.5 seconds (range, 92 – 219), respectively. In this group,
no dog attained the machine cut-off closure time of greater than 300 seconds at any time
point. In the incomplete aspirin responder group, mean closure time on Day 0 were 125.4
seconds (range, 72-155). 4 dogs had closure times of greater than 300 seconds on Day 3,
and the other 4 dogs had closure times of greater than 300 seconds on Day 10. In the
aspirin responder group, the mean closure time on Day 0 was 172.5 seconds (range, 90 –
248). In this group, all dog attained the machine cut-off closure time of greater than 300
seconds on both Day 3 and Day 10. Mean closure times during aspirin administration
could not be calculated in the incomplete aspirin responder and the aspirin responder
groups because, at each time point, a number of dogs exceeded the machine cut-off
closure time.

Platelet COX-1 and COX-2 Expression
Platelet expression of COX-1 and COX-2 was measured prior to and at all tested
time points during aspirin administration. There was a significant increase in platelet
COX-1 expression from Day 0 to Day 3 by 19% (range, -29.7%-136.1%) (P = 0.047) and
from Day 0 to Day 10 with an mean increase of 71.9% (range, -0.37- 210.36%) (P <
0.001). (Figure 3.1) There was also a significant (P < 0.001) increase in mean COX-1
expression from Day 3 to Day 10 by 56.5% (range, -24.7-241.4%). There were no
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significant (P = 0.958) differences in COX-1 expression between the three groups of
aspirin responsiveness.

Figure 3.1

Mean platelet COX-1 expression during treatment of 24 healthy dogs with
low dose aspirin (1 mg/kg PO every 24 hours for 10 days). There was a
significant increase in COX-1 expression from Day 0 to Day 3 (P = 0.047)
(*) and from Day 0 to Day 10 (P < 0.001) (**). There was also a
significant (P < 0.001) increase between Day 3 and Day 10.
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Platelet COX-2 expression was significantly (P = 0.003, P <0.001 respectively)
increased from Day 0 to Day 3 by 43.82% (range, -29.2- 270.4%) and from Day 0 to Day
10 by 75.1% (range, -19.7- 226.2%). (Figure 3.2) COX-2 expression was also
significantly (P = 0.014) increased between Days 3 and 10 by 26.5% (range, -27.3117.2%). Similar to the COX-1 expression, there were no significant (P = 0.479)
differences in COX-2 expression between the three groups of aspirin responsiveness.

Figure 3.2

Mean platelet COX-2 expression during treatment of 24 healthy dogs with
low dose aspirin. There was a significant increase in COX-2 expression
from Day 0 to Day 3 (P = 0.003) (*) and from Day 0 to Day 10
(P < 0.001) (**). There was also a significant (P = 0.014) increase
between Day 3 and Day 10.
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Urinary Thromboxane Concentration
The mean urine 11-dTXB2 to creatinine ratio on Day 0 was 10.8 (range, 4.0-38.5),
while the mean ratios for Day 3 and Day 10 were 7.5 (range, 3.2-18.2) and 5.2 (range,
1.2-11.8), respectively. There was a 23% decrease in the urine 11-dTXB2 to creatinine
ratio between Day 0 and Day 3, while there was a 43.9% decrease between Day 0 and
Day 10 and 23.9% decrease between Day 3 and Day 10. (Figure 3.3) Significant
decreases in the urinary 11-dTXB2 to creatinine ratio occurred at all time points, from
Day 0 to Day 3 (P = 0.005), from Day 0 to Day 10 (P < 0.001), and from Day 3 to Day 10
(P = 0.014). Only 4 dogs on Day 3 and 2 dogs on Day 10 had an increase in the 11dTXB2 to creatinine ratio. There were no significant (P = 0.885) differences in the urine
11-dTXB2 to creatinine ratio between the three groups of aspirin responsiveness.
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Figure 3.3

Mean urinary 11-dTXB2 to creatinine ratios during treatment of 24 healthy
dogs with low dose aspirin. There was a significant decrease in the
urinary 11-dTXB2 to creatinine ratio from Day 0 to Day 3 (P = 0.005) (*)
and from Day 0 to Day 10 (P < 0.001) (**). There was also a significant
(P = 0.014) decrease between Day 3 and Day 10.
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Discussion
Anti-inflammatory doses of aspirin reliably inhibit platelet function in dogs.6,7,19
Our study revealed that low dose aspirin, in contrast, does not inhibit platelet function in
all dogs as measured using the PFA-100® collagen/epinephrine cartridge, suggesting that
aspirin resistance may occur in dogs as well as in humans. Chronic low dose aspirin
administration did inhibit thromboxane synthesis in most dogs: although 4 dogs on Day 3
and 2 dogs on Day 10 demonstrated increased urine 11-dTXB2 to creatinine ratios, all of
the dogs in the study at least once had a decreased 11-dTXB2 to creatinine ratio. The
inhibition of thromboxane by low dose aspirin did not appear to correlate with aspirin
responsiveness as measured by the PFA-100®. With no differences in urinary
thromboxane concentrations between aspirin responders, non-responders, and
inconsistent responders, our study suggests that COX-1 independent thromboxane
synthesis, either through the COX-2 enzyme pathway or alternative pathways, is unlikely
to be the mechanism for aspirin resistance in dogs.
One possible explanation for aspirin resistance in dogs may be variable
responsiveness of platelets to thromboxane. Previous studies have suggested that about
70% of canine platelets are insensitive to thromboxane stimulation.29-31 The
thromboxane insensitivity observed in some canine platelets may be due to impaired
platelet thromboxane A2 receptor linked G proteins.31 If only 30% of dogs have platelets
that are sensitive to the effects of thromboxane, this may explain why only one third of
the animals in our study responded to low dose aspirin with a consistent increase in PFA100 closure time. In those dogs that have platelets that are insensitive to thromboxaneinduced activation, other agonists such as ADP or serotonin may play a more important
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role in platelet activation, and such dogs may therefore be relatively resistant to the
inhibitory effects of low dose aspirin. A recent human study suggests that resistance to
aspirin may be due to a COX independent pathway and that, in affected people, inhibition
of platelet function is more readily achieved using an ADP antagonist.12
We measured urine levels of the thromboxane metabolite 11-dehydrothromboxane B2 to evaluate the effects of aspirin on platelet thromboxane synthesis.
Measurement of this metabolite has been utilized in previous studies as an indicator of
aspirin-induced COX inhibition.32-34 Following synthesis by platelets, thromboxane A2
has an immediate physiologic effect, and is then metabolized to thromboxane B2 and
further metabolized into 11-dehydro-thromboxane B2 and 2,3-dinor-thromboxane B2
(2,3-dinorTXB2) before being eliminated in the urine.8,34,35 Levels of thromboxane
metabolites in plasma or serum can be artifactually increased due to platelet activation
during collection of blood and sample processing. The use of urine to measure
thromboxane metabolites avoids the problem of in-vitro platelet activation associated
with blood collection, and is therefore considered to be a more reliable indicator of
platelet thromboxane synthesis.34,35
Although most dogs in this study had a persistent decrease in urine 11-dTXB2 to
creatinine ratios after administration of low dose aspirin, and every dog had a decreased
ratio for at least one time point, a few dogs demonstrated an increased ratio at a single
time point. Similar inconsistent inhibition of urine 11-dTXB2 levels has previously been
reported in dogs in a study using the same low dose of aspirin.8 This previous study also
evaluated urinary 2,3-dinor-thromboxane B2 and demonstrated that, compared to 11dTXB2, urine 2,3-dinorTXB2 levels were a more sensitive indicator of aspirin-induced
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thromboxane inhibition in dogs.8 However, although the urine 11-dTXB2 assay used in
our study is less sensitive for detecting aspirin-induced thromboxane inhibition compared
to the urine 2,3-dinorTXB2 assay, our assay was still sufficiently sensitive to detect a
significant decrease in urine thromboxane metabolites at both measured time points after
aspirin administration.
While cyclooxygenase function was demonstrably inhibited by low dose aspirin
as indicated by prolongation of PFA-100® collagen/epinephrine closure times and
decreased urine 11-dTXB2 levels, platelet expression of both COX-1 and COX-2
progressively increased throughout the course of aspirin administration. The COX-1
enzyme isoform was originally thought to be strictly constitutively expressed, but recent
studies have shown that COX-1 expression can be induced in certain tissues, including
human megakaryoblasts during thrombocytopoiesis.15,36,37 Similar to the results of this
study, a previous study has demonstrated that anti-inflammatory doses of aspirin also
cause increased platelet COX-1 expression, decreased thromboxane synthesis, and
inhibition in platelet function.19 One possible explanation for increased platelet COX-1
expression could be a compensatory up-regulation of production of the COX-1 isoform
by megakaryocytes in response to a reduction in platelet thromboxane A2 production.
Platelet COX-2 expression also increased during administration of low dose aspirin, a
finding that contrasts with a previous study in dogs treated with an anti-inflammatory
dose of aspirin, in which platelet COX-2 expression decreased in most treated dogs.19
Since COX-2 expression is typically induced by inflammatory mediators,15,38,39 it is
feasible that the anti-inflammatory effects of high doses of aspirin are sufficient to
decrease COX-2 expression, whereas the low dose of aspirin used in our current study
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was insufficient to exert the same effect. At low doses of aspirin, the mechanism of
increased platelet COX-2 expression could be similar to the mechanism of increased
COX-1 expression.
Pre-treatment patient-to-patient variations in platelet COX-1 and COX-2
expression have been proposed as one potential mechanism for variable aspirin
responsiveness. Our current study, however, did not demonstrate a difference in pretreatment platelet COX-1 or COX-2 expression between the three categories of aspirin
responsiveness. Our results suggest that differences in pre-treatment platelet COX
expression do not play a major role in aspirin resistance in dogs, and indicate that preexisting COX expression cannot be used to predict aspirin responsiveness
Platelet aggregometry has long been considered the gold standard methodology
for the evaluation of platelet responsiveness to aspirin.7,40 Platelet aggregometry is,
however, expensive and requires specialized equipment and training, thus making it
difficult to utilize this technology in a clinical setting. The PFA-100®, in contrast, is an
instrument that is practical for routine clinical use, and prolongation of the PFA-100®
closure time as measured with the collagen/epinephrine cartridge has become well
established as a sensitive indicator of aspirin-induced platelet dysfunction in both humans
and dogs.7 The PFA-100® closure times in our present study revealed that only one third
of healthy dogs responded adequately and consistently to low dose aspirin therapy. If our
study is an accurate representation of the canine population, the administration of a 1
mg/kg per day dose of aspirin may not be adequate to create a consistent and reliable
preventive therapy for thromboembolic complications in a majority of dogs. Antiinflammatory doses of aspirin (10 mg/kg bid), in contrast, have been shown to
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consistently inhibit platelet function in dogs.19 Commencement with low dose aspirin at
1 mg/kg per day and subsequent utilization of periodic measurement of platelet function
via the PFA-100® to individually dose escalate ‘to effect’ could increase the population
of aspirin responders and thereby more effectively prevent thromboembolic
complications. The aspirin responders in our study had inhibition of platelet function by
Day 3 of therapy, suggesting that platelet function analysis after three days of aspirin
should be adequate to detect whether a patient will respond to the current dose of aspirin,
or require a higher dose. However, as the aspirin dose increases, so does the chance of
developing adverse side effects. Furthermore, as aspirin dosage approaches antiinflammatory doses, the likelihood of concurrent inhibition of prostacyclin production by
the vascular endothelium increases, potentially negating the anti-platelet effects of
aspirin.
There were several limitations to our study. While our study population consisted
of a variety of breeds and ages, we evaluated aspirin effects only in healthy dogs.
Responsiveness to aspirin could vary in the presence of endogenous platelet activation,
and a similar study in dogs with pro-inflammatory or prothrombotic diseases would be
necessary to determine the incidence of aspirin resistance in sick patients. Additionally,
our study used no methods to ensure that all patients received the appropriate daily dose.
Although it is unlikely, a lack of owner compliance might explain why some dogs either
did not respond or inconsistently responded to the aspirin dose. Due to unexpected dropout of several owners at the start of the study, and the exclusion of one dog because of a
prolonged baseline PFA-100® collagen/epinephrine closure time, the study was
completed with 24 dogs rather than the minimum of 27 dogs suggested by preceding
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power analysis. However, despite this slight reduction in the number of enrolled dogs,
animal numbers were still sufficient to detect significant post-aspirin changes in platelet
function, platelet COX expression, and thromboxane production.
Our study demonstrates that low dose aspirin inhibits platelet thromboxane
synthesis and increases platelet expression of both COX-1 and COX-2, while inhibition
of platelet function is less consistently observed in individual dogs. Platelet COX
expression before and during therapy was not related to aspirin responsiveness.
Additional research is needed to better define the mechanism of aspirin resistance in
dogs.

Materials, Instruments, and Supplies
a. Shearer L, Kruth SA, Wood D. Effects of aspirin and clopidogrel on platelet function
in healthy dogs (abstr). J Vet Intern Med 2009; 23: 745.
b. PFA-100®, Siemens Healthcare Diagnostics, Deerfield, IL
c. PFA Collagen/ADP Test Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
d. Aspirin, Major Pharmaceuticals, Livonia, MI
e. PFA Collagen/Epinephrine Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
f. 3.8% sodium citrate, Vacutainer tube, Becton Dickinson, Franklin Lakes, NJ
g. FITC-conjugated monoclonal COX-1, Cayman Chemical Co, Ann Arbor, MI
h. Monoclonal anti-human CD9:RPE, Clone MM2/57, AbD Serotec, Raleigh, NC
i. Paraformaldehyde, Biolegend Inc., San Diego, CA
j. Triton X-100, Sigma-Aldrich, St. Louis, MO
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k. FITC-conjugated monoclonal COX-2, Cayman Chemical Co, Ann Arbor, MI
l. Monoclonal CD61-purified, Clone JM2E5, Accurate Chemical, Westbury, NY
m. Goat anti-mouse IgG:RPE, AbD Serotec, Raleigh, NC
n. FACSCalibur, Becton Dickinson, San Jose, CA
o. CellQuest software, Becton Dickinson, San Jose, CA
p. Luminex® 200 System xMAP Technology, Luminex Corporation, Austin, TX
q. Luminex® 11-dehydro Thromboxane B2 Kit, Cayman Chemical Co, Ann Arbor, MI
r. ACE Alera® Clinical Chemistry System, Alfa Wasserman, Inc., West Caldwell, NJ
s. SAS for Windows version 9.2, SAS Institute, INC., Cary, NC, 2008
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CHAPTER IV
THE EFFECTS OF CYCLOSPORINE ON PLATELET FUNCTION AND
CYCLOOXYGENASE EXPRESSION IN NORMAL DOGS
Introduction
Cyclosporine has become a popular treatment for allergic dermatitis,1,2 anal
furunculosis,3-6 and several other immune-mediated and inflammatory diseases in dogs,
including immune-mediated hemolytic anemia (IMHA). This is due partly to the
perception that cyclosporine has a more favorable side effect profile when compared to
other immunosuppressive agents.7 Recent human studies, however, have shown that
cyclosporine can alter the platelet plasma membrane, increase the thrombogenic
properties of platelets, and accelerate thrombin generation.8-11 Approximately 50% of
dogs with IMHA have been shown to be in a hypercoagulable state, predisposing these
patients to complications such as pulmonary thromboembolism (PTE).12 The incidence
of PTE in dogs with IMHA has been determined to be over 30%,5,13 however, due to the
difficulty in making an antemortem diagnosis, it is possible that the incidence of PTE in
such patients may be as high as 80%.13 Minimizing risk factors for thromboembolic
complications plays an important role in the treatment of IMHA patients.
This chapter has been submitted for publication to the Journal of Veterinary
Internal Medicine. Thomason J, Lunsford K, Stokes J, Pinchuk L, Wills R, Langston C,
Pruett S, Mackin A. The Effects of Cyclosporine on Platelet Function and
Cyclooxygenase Expression in Normal Dogs.
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The exact mechanisms of PTE formation are not completely understood, but it is
hypothesized that predisposing pro-thrombotic conditions involve both blood platelets
and the clotting system.12,14 Dogs with IMHA have been shown to have hyperactive
platelets associated with platelet plasma membrane alteration and increased expression of
P-selectin, an adhesion protein with procoagulant properties.14 Results of several studies
have suggested that cyclosporine may enhance platelet reactivity,9-11 a finding that raises
doubt about the safety of administering the drug to IMHA patients already at increased
risk for PTE formation. A recent pilot study performed in our laboratory using a small
number of dogs found increased platelet P-selectin expression after administration of
cyclosporine.a The administration of cyclosporine has also been associated with
increased platelet expression of phosphatidylserine, which acts as a catalyst for thrombin
generation and expedites thrombus formation.8 Cyclosporine has also been shown to
increase human platelet production of thromboxane A2.15-18 Thromboxane A2 is
synthesized and released by activated platelets, and triggers vasoconstriction, enhanced
platelet aggregation, and further platelet activation. Platelet thromboxane A2 is generated
via the enzyme cyclooxygenase (COX), which exists in two major forms, COX-1 and
COX-2. Although it was long believed that platelets did not contain COX-2, recent
studies have identified platelet COX-1 and COX-2 expression in humans and dogs.19-21
Our current study was designed to thoroughly evaluate the effects of cyclosporine
on hemostasis in normal dogs, concentrating on platelet function, thromboxane
production and expression of P-selectin, phosphatidylserine, COX-1 and COX-2, and
thereby ascertain whether treatment with cyclosporine could feasibly put canine IMHA
patients at an increased risk of thromboembolic complications.
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Material and Methods
Study Design
Eight healthy female intact Walker hound dogs were used in this study. The dogs
were not exposed to any medications or vaccines for at least one month prior to initiation
of the study. Two dose rates of oral cyclosporineb were administered for 7 days each, a
high (immunosuppressive) dose followed by a low (atopy) dose, with a 2 week washout
period between dosing. For the high dose, cyclosporine was commenced at a dose rate of
approximately 10 mg/kg twice daily, and blood samples were collected from each dog on
Day 4 of drug administration 12 hours after the previous dose in order to determine
trough cyclosporine blood levels using high-performance liquid chromatography (HPLC)
analysis. A target immunosuppressive trough blood level was set at 600 ng/ml,22 and
drug doses were adjusted upwards if needed to ensure that the trough blood levels exceed
this target level by the time of sample collection on Day 7. The mean administered
dosage of the high dose of cyclosporine was 10.1 mg/kg + 0.48 (mean + SD) mg/kg, PO,
q 12 hours, at the time of drug commencement, but mean dosage had increased to 19 + 9
mg/kg, PO, q 12 hours, by Day 7. The mean administered dosage for the low dose of
cyclosporine was 5.1 + 0.21 mg/kg, PO, q 24 hour. Drug doses were not adjusted during
administration of the low dose of cyclosporine.
Blood and urine samples were collected at regular intervals for platelet function
testing, flow cytometric evaluation of platelet P-selectin, phosphatidylserine, COX-1 and
COX-2 expression, and urinary thromboxane analysis. For both drug doses, blood and
urine samples were collected at baseline prior to cyclosporine administration, and on
Days 1 and 7 of drug administration. Samples were collected at 2 time points on each
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day of collection, at the estimated times of peak and trough cyclosporine levels. Samples
were collected at estimated peak blood drug levels 2 hours after drug administration for
both doses, and at estimated trough blood drug levels 12 hours after drug administration
for the high dose, and 24 hours after drug administration for the low dose.

Animals
The mean age of the dogs was 5.5 years (range, 1.5-6.5 years), and their mean
body weight was 22.7 kg (range, 18.2 to 28.6 kg). Body weight was obtained at the
beginning of the study and used to calculate all subsequent dosing. Normal health status
was established by detection of no abnormalities on physical examination, complete
blood count (including manual platelet count), serum biochemistry, urinalysis,
prothrombin time, partial thromboplastin time, fibrinogen, buccal mucosal bleeding time,
vonWillebrand factor (ELISA method), Babesia and rickettsial serology, and heartworm
testing. One dog developed pyometra during the washout period between doses, and did
not continue in the study. Animal use was approved by the Mississippi State University
Institutional Animal Care and Use Committee and was in compliance with the
requirements at a facility accredited by the American Association for Accreditation of
Laboratory Animal Care.

Flow Cytometry
Blood was collected via jugular venipuncture with a 20 gauge needle directly into
a glass vacutainer tube containing 3.8% sodium citrate.c Sample preparation for flow
cytometry was initiated within 2 hours of collection.
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P-selectin labeling: Previously described protocols14,23,24 were modified for the
detection of platelet P-selectin (CD62). Briefly, 5 µL of citrated whole blood was added
to 45 µL of FACS-PBS and incubated in the dark at room temperature with an affinitypurified, monoclonal, mouse anti-canine CD62 antibody.d After incubation, samples
were washed with PBS, pelleted via centrifugation, and re-suspended. Goat, anti-mousePEe conjugate was added to all samples and incubated in the dark at room temperature for
30 minutes. For platelet identification, samples were incubated with monoclonal FITCconjugated mouse anti-porcine CD61f, and fixed with 1% paraformaldehydeg for ten
minutes at 4oC in the dark.
Phosphatidylserine labeling: A previously described protocol was used to detect
platelet phosphatidylserine.23 Briefly, 5 µL of citrated whole blood was added to 250 µL
of annexin-binding buffer.h Samples were incubated with annexin-V-FITCi and mouse
anti-porcine CD61-purified antibodyj for 30 minutes in the dark at room temperature.
After incubation, goat anti-mouse IgG:RPEk was added to the samples, followed by a 30
minute incubation. Samples were fixed with 1% paraformaldehyde for 10 minutes.
COX-1 labeling: A previously described protocol21 was used to quantify platelet
COX-1 expression. Briefly, 5 µL of citrated whole blood was added to 45 µL of FACSPBS and incubated with ovine COX-1 specific monoclonal antibody.l To identify
platelets, samples were incubated with a monoclonal antibody to human CD9.m Samples
were fixed for 10 minutes at 4oC in the dark with 1% paraformaldehyde.
COX-2 labeling: Analysis of canine platelet COX-2 expression was performed
using a modification of a human protocol19 that has been previously reported in dogs.21
Briefly, 5µL of citrated whole blood was added to 45 uL of FACS-PBS and fixed at 4oC
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in the dark with 1% paraformaldehyde. Samples were washed, pelleted, re-suspended,
and incubated in 0.3% Triton X-100n followed by another wash. Samples were then
incubated with a monoclonal FITC-conjugated mouse anti-human-COX-2 antibodyo in
the dark at room temperature. Platelets were identified with a monoclonal antibody to
porcine CD61 and goat anti-mouse IgG:RPE antibody.
All samples were stored in the dark at 4oC prior to flow cytometric analysis.
Isotype matched monoclonal antibodies were used for all marker specific antibodies.
Flow cytometric analysis was performed with a flow cytometerp with CellQuest Pro
software.q Platelet populations were displayed on log forward-scatter versus log sideangle light scatter plots. Gates were adjusted to baseline platelet populations, and a total
of 5,000 gated events were recorded for each labeling. Expression was quantified by the
intensity of antibody fluorescence and expressed as mean fluorescence intensity (MFI).
A histogram was created with MFI on the x-axis and platelet number on the y-axis.

Urinary Thromboxane
Urinary 11-dehydro-thromboxane B2 (11-dTXB2) concentration was analyzed
using a commercially available competitive enzyme immunoassay kitr for a multiplex
analyzers that has been previously validated in the dog.25 Urine was collected via
cystocentesis, batched, and stored at -80oC until analysis. The assay buffer was used to
standardize the urine specific gravity of each sample to fit within the working range
(1.003 to 1.012) of the analyzer, and a correction factor was applied to account for these
dilutions. Samples were analyzed in duplicate according to the manufacturer’s
instructions, and reported in picograms per milliliter of urine. Briefly, a 96-well plate was
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prepared by adding 100 µl of each sample and 50 µl of both 11-dTXB2 phycoerythrin
tracer and 11-dTXB2 XMAPR® Beads to each well. Prior to analysis, each plate was
incubated at room temperature, in the dark and on an orbital shaker, for 4 hours. Urine
creatinine concentration was measured using a biochemistry analyzert and the 11-dTXB2
concentration was normalized to create a urinary 11-TXB2to creatinine ratio.25,26

Platelet Function Analysis
A commercial point-of-care platelet function analyzer (PFA-100®)u that has been
previously evaluated for use in dogs was used to analyze platelet function.27-30 The PFA100® is an in vitro platelet function analyzer that mimics an environment similar to blood
vessels and stimulates platelet function with several platelet agonists to measure the time,
in seconds, needed to form a platelet plug and inhibit blood flow. The cut-off time for
the instrument is greater than 300 seconds.
The instrument was used according to manufacturer’s instructions. Briefly,
samples were collected directly into 5 ml blood collection tubes containing 3.8% sodium
citrate, and 800 µl of whole blood sample was transferred into PFA-100® cartridges (both
collagen/ADP and collagen/epinephrine)v,w and analyzed. All samples were analyzed
within three hours of collection. An automated hematologic analyzerx was used to
determine an accurate platelet count and packed cell volume (PCV) on each sample.
Cartridges were stored at 4oC and warmed to room temperature before analysis.
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Cyclosporine Assay
Measurement of peak and trough blood cyclosporine levels was performed via
HPLC analysis based on a modification of the therapeutic drug monitoring assay used at
the University of California at Davis.y Briefly, blood was collected into tubes containing
EDTAz anticoagulant, batched, and stored at -80oC until analysis. Samples were thawed
and underwent an extraction procedure that mixed 2 mLs of the whole blood sample with
a protein precipitating solution that consisted of 5% zinc sulfate, 20% acetonitrile, 30%
methanol, water, and an internal standard of 400 ng/ml of cyclosporine D.aa Samples
were mixed, centrifuged, and the supernatant was added to a prepared C18 solid phase
extraction (SPE) column.bb The SPE column, under vacuum, was washed with 5 mls of
50% acetonitrile and then the cyclosporine was eluted by 1 ml of 100% methanol. To the
eluent, 200 µL of water followed by 300 µL of hexane was added. This sample was
centrifuged at 14.5 revolutions per minute for 90 seconds and 200 µL of the aqueous
layer was extracted and prepared for HPLC analysis. Only 100 µL of the sample was
injected for HPLC analysis. Blank EDTA whole blood was used for a standard curve
with cyclosporinecc at 0, 200, 400, 800, and 1600 ng/ml.
Cyclosporine analysis was performed using an Agilent 1100 HPLC systemdd with
degasser (G1322A), quaternary pump (G1311A), autoinjector (G1313A), and diode array
detector (G1315). The reverse phase column was a Phenomenex Luna 5u C18 (2) (150 x
2.00 mm 5 micron) which was maintained at 75oC. A 1 mL per minute gradient mobile
phase consisted of acetonitrile (A) and water adjusted to pH 3.1 (B). The gradient
transitioned linearly from 65% A and 35% B to 70% A and 30% B over 5 minutes, and
held for 15 minutes. After each injection, there was a 5 minute re-equilibration time
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period. Detection was at 200 nm. The retention time for cyclosporine and cyclosporine
D was 4.2 min and 5.6 minutes, respectively. The assay was linear over the standard
curve range with an r2 of 0.98. The assay had an average coefficient of variation of 6.7%
(range 3.7 to 9.9%) and an average accuracy of 94.4% (range 92 to 98%).

Statistical Analysis
A single population, repeated measures design was utilized in this study. Visual
assessment of the data using Q-Q plots and histograms with UNIVARIATE procedure of
SAS for Windows 9.2 (SAS Institute, Inc., Cary, NC, USA) indicated the data was not
consistently normally distributed for all of the outcomes. Consequently, nonparametric
methods for analysis of repeated measures were utilized. For all four flow cytometry
assays, PCV, platelet count, PFA-100®, and urine 11-dTBX2, the data were ranked and
then analysis of variance type statistics were obtained through the MIXED procedure of
SAS for Windows 9.2 by using the ANOVAF option and the MIVQUE0 estimation
method for the covariance parameters and a REPEATED statement specifying an
unstructured covariance structure. Each dose of cyclosporine was analyzed separately
from the other dose, and the results were not compared. Sample time was included in the
model as a fixed effect. For outcome in which time had a significant effect (p≤0.05),
comparisons were made between baseline and the other time points using differences in
least square means. Paired T-Tests using the UNIVARIATE procedure of SAS for
Windows 9.2 were conducted to compare baseline levels of outcomes prior to high dose
and low dose administration and between baseline levels prior to high dose
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administration and levels following the washout period A p-value of less than or equal to
0.05 was considered to be significant for all analyses.

Results
Flow Cytometry
Platelet expression of P-selectin, phosphatidylserine, COX-1 and COX-2 was
measured both prior to and at all tested time points during drug administration, and
percent change in MFI compared to baseline for all four markers is represented in
Table 4.1.
There was a significant decrease in platelet P-selectin expression at all time points
during administration of the high dose of cyclosporine, compared to baseline levels.
During the administration of the low dose, P-selectin expression only significantly
decreased at both trough time points (Figure 4.1).
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Table 4.1
The percent change in MFI from baseline for all flow cytometry markers (P-selectin,
phosphatidylserine, COX-1 and COX-2) during administration
of both cyclosporine doses
High Dose Cyclosporine

Low Dose Cyclosporine

Percent (%) MFI Change
compared to baseline

P-value

Percent (%) MFI Change
compared to baseline

P-value

Day 1 – Peak

-48.0

0.003*

-12.0

0.587

Day 1 – Trough

-56.3

0.004*

-43.5

0.007*

Day 7 – Peak

-36.7

0.019*

3.0

0.600

Day 7 – Trough

-35.0

0.025*

-28.8

0.013*

Day 1 – Peak

-69.7

<0.001*

-14.1

0.022*

Day 1 – Trough

-70.1

<0.001*

31.8

0.022*

Day 7 – Peak

-66.6

<0.001*

5.9

0.496

Day 7 – Trough

-68.2

<0.001*

6.4

0.780

Day 1 – Peak

-14.7

0.250

-21.2

0.029*

Day 1 – Trough

-27.6

0.035*

-25.6

0.022*

Day 7 – Peak

-38.5

0.004*

-51.2

<0.001*

Day 7 – Trough

-40.8

0.002*

-2.0

0.555

148.9

<0.001*

-32.4

<0.001*

9.4

0.349

5.7

0.458

Day 7 – Peak

-42.3

<0.001*

-17.9

0.114

Day 7 – Trough

-33.5

0.001*

-30.5

0.003*

P-selectin

Phosphatidylserine

COX-1

COX-2
Day 1 – Peak
Day 1 – Trough

MFI = Mean Fluorescence Intensity

Statistical Significance *
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Figure 4.1

Mean P-selectin expression for all dogs treated with two doses of cyclosporine (High Dose = mean 19 mg/kg
PO every 12 hours, and Low Dose = 5 mg/kg PO every 24 hours). There was a significant decrease from
baseline values in P-selectin expression at all time points after the high dose of cyclosporine (*). However, only
the two trough time points showed a significant decrease during the low dose (**).

There was also a significant decrease in platelet phosphatidylserine expression at
all time points during administration of the high dose of cyclosporine, compared to
baseline levels. The initial baseline result prior to the high dose trial was considerably
greater than all subsequent time points, including the low dose trial baseline. In order to
confirm that this elevated initial baseline result was not erroneous, blood samples were
obtained for repeat analysis of platelet phosphatidylserine expression on two different
days after a prolonged washout time period. The mean of these two repeat samples were
greater than all other time points, but the MFI was still significantly (p=0.008) less than
the initial baseline result. Significant changes in phosphatidylserine expression observed
during the administration of the low dose of cyclosporine were a decrease at the peak
time point and an increase at the trough time point on Day 1 (Figure 4.2).
Compared to baseline levels, there was a significant decrease in platelet COX-1
expression at both trough time points and at the peak time point on Day 7 during
administration of the high dose of cyclosporine. During the administration of the low
dose, there was a significant decrease in COX-1 expression at both time points on Day 1,
and Day 7 peak (Figure 4.3).
Compared to baseline levels, there was an immediate significant increase in
platelet COX-2 expression two hours after initiation of the high dose of cyclosporine
(Day 1 peak time point). However, there was then a decline in platelet COX-2
expression until there was a significant decrease in COX-2 expression at both the peak
and trough time points on Day 7. During administration of the low dose of cyclosporine,
there was a significant decrease in platelet COX-2 expression two hours after drug
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Figure 4.2

Mean phosphatidylserine expression for dogs treated with two doses of cyclosporine. There was a significant
decrease from baseline values in phosphatidylserine expression at all time points after the high dose of
cyclosporine (*), while during the low dose study the Day 1 peak showed a significant decrease (**), and Day 1
trough showed a significant increase (***).
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Figure 4.3

Mean COX-1 expression for dogs treated with two doses of cyclosporine. During the high dose of
cyclosporine, COX-1 expression was significantly decreased from baseline values by the Day 1 trough time
point, and remained significantly decreased for the remainder of drug administration (*). Three time points
(Day 1 peak and trough and Day 7 peak) were significantly decreased during the low dose (**).

initiation (Day 1 peak time point). Platelet COX-2 expression then returned to levels
comparable with baseline values 24 hours after administration of the first dose. Platelet
COX-2 expression was again significantly decreased at the final time point (Day 7
trough) (Figure 4.4).

Urinary Thromboxane
The mean baseline urinary 11-dTXB2 to creatinine ratio was 18 (range 10.7-24.7)
prior to the high dose of cyclosporine. Following administration of the high dose, there
was a significant increase in the urinary 11-dTXB2 to creatinine ratio compared to
baseline values at all time points. The peak time points on Day 1 and 7 had the highest
percent increase in the mean 11-dTXB2 to creatinine ratio, with increases of 1,027%
(mean ratio 203; range 15.6-623) (p=0.004) and 1,461% (mean ratio 281.2, range 47.8799.3) (p<0.001), respectively. There was also a significant increase in the mean baseline
urinary 11-dTXB2 to creatinine ratio at trough time points on Day 1 and 7, with increases
of 142.7% (mean ratio 43.71; range 19.2-69.39) (p=0.001) and 107.6% (mean ratio
37.38; range 13.83-67.77) (p<0.047), respectively (Figure 4.5). Urine was not available
from one dog at the peak time period on Day 1.
The mean baseline urinary 11-dTXB2 to creatinine ratio was 16.7 (range 8.3-28.2)
prior to the low dose of cyclosporine. There was no significant change in the urinary 11dTXB2 to creatinine ratio compared to baseline values at any time point (Figure 4.5).
Urine was not available from one dog at the peak time point on Day 1, from three dogs at
the peak time point on Day 7, and from two dogs at each trough time point.
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Figure 4.4

Mean COX-2 expression for dogs treated with two doses of cyclosporine. COX-2 expression was significantly
decreased from baseline values by the end of administration (Day 7 peak and trough time points) of the high
dose of cyclosporine (*). However, there was also a significant increase in COX-2 expression within 2 hours of
initiating the high dose (**). With the low dose, there was an overall decrease in COX-2 expression, but only
two time points (Day 1 peak and Day 7 trough) reached significance (***).
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Figure 4.5

Mean urinary 11-dTXB2 to creatinine ratios for dogs treated with two doses of cyclosporine. Urinary 11dTXB2 to creatinine ratios significantly increased from baseline values at all time points during the high dose of
cyclosporine (*). No significant changes were detected during the low dose of cyclosporine.

Platelet Function Analysis
The mean baseline PFA-100® closure time using the collagen/ADP cartridge was
95.6 seconds (range 69-172 seconds) prior to the high dose of cyclosporine. There was
an immediate significant (p=0.006) increase in closure time two hours after the
administration of the initial high dose of cyclosporine (Day 1 peak time point), on
average by 100%. However, after this first time point, the mean closure time dropped to
30%, 35%, and 62% above baseline at the remaining three time points, respectively. The
Day 7 peak and trough time point closure times were still significantly increased (P=
0.005 and 0.008, respectively) (Figure 4.6).
The mean baseline PFA-100® closure time using the collagen/ADP cartridge was
140.6 seconds (range 67-234 seconds) prior to the low dose of cyclosporine. There was a
significant (p=0.037) decrease in closure time twenty four hours after the administration
of the initial low dose of cyclosporine (Day 1 trough time point), on average by 42.9%
(Figure 4.6). Closure times remained significantly decreased for all remaining time
points.
The mean baseline PFA-100® closure time using the collagen/epinephrine
cartridge was 164.8 seconds (range 117-229 seconds) prior to the high dose of
cyclosporine, and 174.9 seconds (range 130-254) prior to the low dose. There was no
significant association between closure times and sample time for either high dose
(p≥0.054) or low dose (p≥0.472) cyclosporine (Figure 4.7).
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Figure 4.6

Mean PFA-100® closure times (seconds) for the collagen/ADP cartridge for dogs treated with two doses of
cyclosporine. Closure times demonstrated a significant increase from baseline values at most time points during
the high dose of cyclosporine (*). In contrast, during the low dose of cyclosporine, there was a significant
decrease in closure times at three time points (**).
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Figure 4.7

Mean PFA-100® closure times (seconds) for the collagen/epinephrine cartridge for dogs treated with two doses
of cyclosporine. There were no significant changes in closure times at any time point with either dose of
cyclosporine.

Other Testing
The mean baseline PCV prior to the high dose of cyclosporine was 45.5% (range
41.1-52.6). Significant differences in mean PCV during the high dose occurred at the
peak time point on Day 1, with a 4.8% decrease (P=0.020), and peak time point on Day 7,
with a 9.2% decrease (P=0.028); while during the low dose, only the peak time point on
Day 1 was significantly different, with an 11% increase (P=0.019). There was no
significant association (p≥0.068) between platelet count and sampling time for either
cyclosporine dose

Discussion
Cyclosporine is one of the more commonly used immunosuppressive agents in
dogs, partly due to the perception of relatively minimal side effects. Several human
studies, however, have suggested that cyclosporine can increase the risk of
thromboembolic complications by altering the platelet surface membrane and increasing
platelet thromboxane production.8-10,31-33 In our study, we showed that cyclosporine does
alter the platelet membrane, and is associated with a significant increase in platelet
thromboxane production.
Our study demonstrated a significant increase in the urinary 11-dTXB2 to
creatinine ratio during the administration of high doses of cyclosporine, especially at
peak cyclosporine blood levels. This effect appears to be dose-dependent, since a similar
but lesser (not sufficient to attain statistical significance) pattern was seen with low doses
of cyclosporine. Our results are similar to previous studies in humans that demonstrate
an increase in thromboxane production during cyclosporine administration in renal
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transplant and coronary artery disease patients.9,10,31-33 When compared to renal
transplant recipients administered azathioprine, patients receiving cyclosporine had
increased thromboxane production and increased rates of thrombus formation within the
renal parenchyma.10 The mechanism for the increase in platelet generated thromboxane
is undetermined, and additional research would be needed to define the effects of
cyclosporine on thromboxane production. Urinary 11-dTXB2 is considered to be a
reliable marker for platelet thromboxane A2 production.25,34,35 Our results therefore
strongly suggest that cyclosporine at standard immunosuppressive doses triggers
enhanced platelet activation in dogs.
Our study also demonstrated that the sustained administration of cyclosporine at
both low and high doses to dogs leads to decreased platelet COX-2 expression. COX-1 is
the primary cyclooxygenase isoform responsible for platelet production of thromboxane,
while COX-2 is the main isoform that controls tissue prostacyclin (prostaglandin I2)
production.36,37 Compared to thromboxane, prostacyclin has the opposite physiologic
effect on primary hemostasis, and these two prostaglandins work in concert to maintain a
balanced, normal hemostatic system. COX-2 derived prostacyclin has been associated
with a protective response to experimentally-induced thrombus formation.38 Decreased
COX-2 expression, in contrast, could lead to an imbalance between thromboxane and
prostacyclin, resulting in relatively higher levels of thromboxane. Previous studies in rats
have demonstrated that cyclosporine suppresses COX-2 expression in a number of
different tissues.39,40 Our study is the first to demonstrate that cyclosporine similarly
decreases COX-2 expression in canine platelets. Additional research is needed to better
define the role of COX-2 in platelets, and the effects of cyclosporine on this enzyme.
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The COX-2 selective NSAIDs, celecoxib and rofecoxib, have been associated
with an increased rate of thromboembolic complications and cardiovascular events in
humans.36,38,41 Several potential explanations have been proposed for this problem,
including inhibition of prostacyclin production,37,42 decreased nitric oxide synthesis, and
enhanced free-radical production.42 Similar to the mechanism proposed with the COX-2
selective NSAIDs, cyclosporine’s inhibitory effect on COX-2 expression could contribute
to an imbalance between prostacyclin and thromboxane production. In fact, previous
studies in rats have demonstrated that prostacyclin production decreased with
cyclosporine administration.33 Also analogous to the mechanism proposed with the
COX-2 selective NSAIDs, cyclosporine has been shown to inhibit the release of
endothelium-derived relaxing factor and epicardial nitric oxide in dogs, leading to a
potential vasoconstrictor effect.43-46 Cyclosporine has also been associated with
increased free-radical production.47-49 Cyclosporine’s effects on prostacyclin, nitric oxide
and free-radical levels could contribute to a hypercoaguable state in a manner comparable
to the COX-2 selective NSAIDs, and could thereby increase the likelihood of
thromboembolic complications.
Our study demonstrated that there was a steady decrease in platelet COX-1
expression with sustained cyclosporine administration, and a similar but less consistent
effect with lower drug doses. As platelet thromboxane production increased as measured
by the urinary 11-dTXB2 to creatinine ratio, platelet COX-1 expression tended to
decrease. Interestingly, an opposite pattern was recently observed in an aspirin study in
our laboratory: when an anti-inflammatory dose of aspirin was administered to dogs, a
decrease in platelet thromboxane production was associated with an increase in platelet
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COX-1 expression.21 Platelet function was concurrently inhibited in the dogs receiving
aspirin, as demonstrated by prolonged PFA-100®collagen/epinephrine cartridge closure
times, and platelet dysfunction was presumed to be due to COX-1 enzyme inhibition.
The results of our aspirin and cyclosporine studies, when considered in combination,
suggest that there may be a negative feedback system between platelet thromboxane
production and platelet COX-1 expression. Additional research would be required to
determine the exact relationship between platelet COX expression and thromboxane
production.
Platelet function was evaluated by the PFA-100® using two different cartridges
containing two different platelet agonist combinations. In humans, the
collagen/epinephrine cartridge has been shown to be more likely to be influenced by
medications, while the collagen/ADP cartridge is considered to be a more general screen
platelet function. In our study, cyclosporine had no significant impact on
collagen/epinephrine cartridge closure times. However, although the
collagen/epinephrine cartridge has been shown to be an excellent assay for drug-induced
decreases in platelet function, it is not known how useful the same cartridge would be at
detecting drug-associated increases in platelet reactivity. Interestingly, with the
collagen/ADP cartridge, high doses of cyclosporine were associated with an increase in
closure times at most time points, while low doses were associated with a decrease in
closure times at all time points (closure times, however, did not depart from reference
ranges in any dog). The reason for these apparently contradictory results with the
collagen/ADP cartridges is unknown.
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In our study, there was an immediate and sustained decrease in platelet
phosphatidylserine expression after administration of high doses cyclosporine. Our
findings are in contrast to the findings reported in a recent human study, which
demonstrated that cyclosporine increased platelet phosphatidylserine expression.8 One
possible explanation for the different results is that in our study we evaluated the effects
of cyclosporine administered in vivo, while the previous human study incubated platelets
with cyclosporine in vitro. While we cannot explain the difference in results, we believe
that an in vivo study such as ours is more likely to reflect what is truly occurring in
patients receiving cyclosporine. However, it also possible that the decrease
phosphatidylserine expression observed in our study is erroneous, since the initial
baseline value prior to our high dose cyclosporine trial was considerably greater than all
other time points, a result that could be explained by a non-repeatable complication with
sample handling or preparation. We also observed slight but statistically significant
changes in platelet phosphatidylserine expression (decrease at the peak time point and an
increase at the trough time point) during the first day of low dose cyclosporine, findings
that are unlikely to be of any clinical relevance.
Upon platelet activation, phosphatidylserine is exposed on platelet surface
membranes and binds to prothrombin, converting prothrombin to thrombin and
enhancing secondary hemostasis.8 Phosphatidylserine is also expressed during apoptosis
of nucleated cells.50-52 Similar apoptotic pathways have been associated with platelet
activation, primarily through opening of the mitochondrial permeability transition pore
(MPTP).53-55 During apoptosis, the MPTP transiently opens and releases several proapoptotic mitochondrial contents into the cell cytoplasm, mediating caspase-3 activation
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and ultimately leading to increased phosphatidylserine expression on the cell surface.52,53
Cyclosporine has been shown to inhibit platelet MPTP function,52 thereby decreasing the
release of mitochondrial pro-apoptoic contents and potentially limiting the amount of
phosphatidylserine expressed on the platelet surface.52,53 Our findings in the high dose
trial, if real, would be consistent with cyclosporine-induced inhibition of MPTP function
and a resultant reduction in platelet phosphatidylserine expression.
Our study demonstrated a significant, immediate and sustained decrease in
platelet P-selectin expression during administration of high doses of cyclosporine. This
effect appears to be dose-dependent, since a similar but less consistent pattern was seen
with the low dose of cyclosporine. Several human studies, in contrast, have demonstrated
an increase in soluble P-selectin in renal transplant recipients treated with
cyclosporine.11,56 In one study comparing renal transplant patients to hypertensive
control patients, P-selectin expression increased with all immunosuppressive agents,
including cyclosporine, although platelet aggregation was not measurably affected.56
Another study also demonstrated an increase in P-selectin expression in renal transplant
recipients treated with cyclosporine, but similarly found no measurable increase in
platelet aggregation.11 Since our study evaluated the effects of cyclosporine on platelet
P-selectin expression in normal dogs, and the human studies evaluated P-selectin
expression in renal transplant recipients, it is possible that cyclosporine has a different
effect in diseased compared to healthy individuals.
Platelet P-selectin is a cell adhesion molecule that mediates platelet and leukocyte
aggregation and generates procoagulant microparticles that contain active tissue factor
and enhance fibrin deposition.57,58 Therefore, like platelet phosphatidylserine, platelet P104

selectin is believed to have procoagulant effects that enhance secondary hemostasis.
Platelet P-selectin expression has been shown to be expressed in higher concentrations in
canine patients with primary IMHA,14 and could contribute to the high rate of
thromboembolic complications seen in IMHA patients. Our previous pilot study, albeit
performed in a small number of animals, demonstrated an increase in platelet P-selectin
expression in dogs receiving cyclosporine, a result that raised concern because
cyclosporine is increasingly used by veterinarians to treat canine IMHA. It is reassuring
that, in this current study using a larger number of dogs and more sustained cyclosporine
dosing, the effect reported in our pilot study was not reproducible and, in fact, a decrease
in platelet P-selectin expression was observed.
One possible explanation for the decrease in platelet P-selectin expression seen in
our study could be a drug-associated inhibition of the pro-inflammatory mediators TNF-α
and IL-1β, which may act as stimulators of P-selectin expression.59-61 Cyclosporineinduced inhibition of TNF-α and IL-1β has been associated with down-regulation of Eselectin, a similar adhesion protein found on vascular endothelium.62,63 Additional
research would be required to evaluate the effect of cyclosporine on platelet P-selectin
expression, soluble plasma P-selectin concentration, and platelet-leukocyte aggregation in
dogs with various diseases, particularly conditions such as IMHA that predispose to a
hypercoagulable state.
Recent human studies have suggested that the use of cyclosporine could lead to an
increase in thromboembolic complications, which would be of considerable concern if
the same phenomenon occurred in canine patients with prothrombotic diseases such as
IMHA. Our study revealed that cyclosporine has multiple effects on canine platelets,
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causing altered expression of proteins on the platelet surface membrane, altered platelet
COX expression, and increased platelet thromboxane production. Since platelets play an
important role in contributing to thrombus formation, it is particularly concerning that the
administration of cyclosporine was associated with marked increases in platelet
thromboxane production, suggesting that exposure to the drug induces platelet activation.
On the other hand, our study also revealed that cyclosporine reduces platelet expression
of the procoagulant proteins P-selectin and phosphatidylserine. Our study was performed
in normal dogs, and our results may not be directly applicable to diseased canine patients.
However, these results strongly suggest that there is a pressing need to evaluate the
effects of cyclosporine on platelet thromboxane production and expression of COX
enzyme isoforms, P-selectin and phosphatidylserine in canine patients that have diseases
that are associated with a hypercoaguable state and predispose to thromboembolic
complications.

Materials, Instruments, and Supplies
a. Thomason J, Lunsford K, Mackin A, et al. Effects of Cyclosporine on Canine Platelet
Procoagulant Activity. J Vet Intern Med. 2009; 23(3): 692.
b. Atopica, Novartis Animal Health, Greensboro, NC
c. 3.8% sodium citrate,Vacutainer tube, Becton Dickinson, Franklin Lakes, NJ
d. Clone MD6, IgG1, generously provided by Dr. C. Wayne Smith, Baylor College of
Medicine, Houston, TX
e. Goat, anti-mouse-PE, Lot Number LXP07, R&D Systems, Minneapolis, MN
f. FITC-conjugated monoclonal CD61, Clone JM2E5, AbDSerotec, Raleigh, NC
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g. Paraformaldehyde, Biolegend Inc., San Diego, CA
h. Annexin-V Binding Buffer, Invitrogen, Camarillo, CA
i. Annexin-V FITC Conjugate (Recombinant), Invitrogen, Camarillo, CA
j. Monoclonal CD61-purified, Clone JM2E5, Accurate Chemical, Westbury, NY
k. Goat anti-mouse IgG:RPE, AbDSerotec, Raleigh, NC
l. FITC-conjugated monoclonal COX-1, Clone CX111, Cayman Chemical Co, Ann
Arbor, MI
m. Monoclonal anti-human CD9:RPE, Clone MM2/57, AbDSerotec, Raleigh, NC
n. Triton X-100, Sigma-Aldrich, St. Louis, MO
o. FITC-conjugated monoclonal COX-2, Clone CX299, Cayman Chemical Co, Ann
Arbor, MI
p. FACS Calibur, BD Biosciences, San Jose, CA
q. CellQuest software, BD Biosciences, San Jose, CA
r. Luminex® 11-dehydro Thromboxane B2 Kit, Cayman Chemical Co, Ann Arbor, MI
s. Luminex® 200 System xMAP Technology, Luminex Corporation, Austin, TX
t. ACE Alera® Clinical Chemistry System, Alfa Wasserman, Inc., West Caldwell, NJ
u. PFA-100®, Siemens Healthcare Diagnostics, Deerfield, IL
v. PFA Collagen/ADP Test Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
w. PFA Collagen/EPI Test Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
x. Abbott Cell-Dyn® 3700, Abbott Laboratories, Abbott Park, IL
y. Personal communication, John D Patz, 2008
z. 7.5% EDTA Blood Collection Tubes, Tyco Healthcare, Mansfield MA
aa. Generous gift from Novartis Pharmaceuticals, East Hanover, NJ
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bb. Varian Bond Elut 100 mg; Agilent Technologies, Santa Clara, CA
cc. Sigma-Aldrich, St. Louis, MO
dd. Agilent Technologies, Santa Clara, CA
ee. SAS for Windows version 9.2, SAS Institute, Cary, NC, 2008
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CHAPTER V
CONCLUSION
Immune-mediated hemolytic anemia (IMHA) is a common cause of anemia in
dogs. Despite aggressive therapy, there is a 50% mortality rate in IMHA patients, and the
most common cause of death is thromboembolic disease. Treatment consists of both
preventative anti-platelet therapy and immunosuppressive medications. Aspirin is
commonly administered to dogs, both for its anti-inflammatory properties and for its antiplatelet effects in order to prevent thromboembolic complications. Cyclosporine has
become a popular immunosuppressive therapy, but in humans has been associated with
an increase in platelet reactivity and thrombus formation. Understanding the relationship
between COX expression and thromboxane synthesis could provide a better
understanding of the interaction between platelets and these two medications.
This research identified the expression of both COX-1 and COX-2 in circulating
canine platelets, and evaluated the changes in both isoforms during the administration of
aspirin and cyclosporine. The COX-1 enzyme isoform was originally thought to be
strictly constitutively expressed, but recent studies have shown that COX-1 expression
can be induced in certain tissues.1 Both of the aspirin studies suggest that exposure to
aspirin induces COX-1 expression in platelets and inhibits thromboxane synthesis.
However, only an anti-inflammatory dose of aspirin consistently inhibits platelet
function, as assessed by the PFA-100® closure times and urinary 11-dTXB2 levels, while
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lower doses of aspirin only inhibit platelet function in about a third of dogs, confirming
the presence of aspirin resistance in normal dogs. One possible explanation for increased
platelet COX-1 expression during aspirin therapy could be a compensatory up-regulation
of the COX-1 isoform by megakaryocytes in response to a reduction in platelet
thromboxane A2 production.
The low dose aspirin study did not demonstrate a difference in pre-treatment
platelet COX-1 expression between the three categories of aspirin responsiveness. Our
results suggest that differences in pre-treatment platelet COX-1 expression do not play a
major role in aspirin resistance in dogs, and indicate that pre-existing COX expression
cannot be used to predict aspirin responsiveness. With no differences in urinary
thromboxane concentrations between aspirin responders, non-responders, and
inconsistent responders, our study suggests that COX-1 independent thromboxane
synthesis is unlikely to be the mechanism for aspirin resistance in dogs.
Sustained cyclosporine administration caused a steady decrease in platelet COX-1
expression, with a similar but less consistent effect with lower drug doses. Unlike the
aspirin studies, platelet thromboxane production increased during cyclosporine
administration. The results of our aspirin and cyclosporine studies, when considered in
combination, suggest that there may be a negative feedback system between platelet
thromboxane production and platelet COX-1 expression.
The high dose aspirin study revealed that, in contrast to COX-1, platelet COX-2
expression decreased from baseline levels during aspirin administration, although the
change was not statistically significant. After discontinuing the medication, however,
there was a significant increase in platelet COX-2 expression, suggesting that high dose
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aspirin does truly decrease platelet expression of this COX isoform. Pro-inflammatory
mediators such as cytokines, endotoxins, and growth factors have been shown to increase
cellular COX-2 expression.2,3 Since inflammation is known to induce cellular COX-2
expression, and we administered a relatively high dose of aspirin, it is possible that the
anti-inflammatory drug dose used served to decrease levels of some of the inflammatory
mediators that induce COX-2.
Interestingly, platelet COX-2 expression increased during administration of low
dose aspirin, a finding that contrasts with the anti-inflammatory dose of aspirin, but that
is comparable to the effects of low dose aspirin on platelet COX-1 expression. It is
possible that the anti-inflammatory effects of high doses of aspirin are sufficient to
decrease or inhibit COX-2 expression, whereas low doses of aspirin were insufficient to
exert the same effect. The COX-2 induction seen at low aspirin doses could possibly be
associated with a negative feedback system with platelet thromboxane production, similar
to COX-1.
Corticosteroids, dexamethasone and other glucocorticoids, have been shown to
decrease cellular COX-2 expression as a result of decreased levels of the inflammatory
cytokines IL-6 and TNF-α.4 Similarly, aspirin has been shown to decrease levels of IL-6
and TNF-α, and would therefore be expected to, like glucocorticoids, decrease cellular
COX-2 expression.5-7 Interestingly, steroid administration has been associated with an
increased risk of thromboembolic complications and in dogs with IMHA, the exact
opposite effect that low dose aspirin has in IMHA patients.8-10 It would interesting to
determine the effect of steroids on platelet COX expression in both healthy dogs and
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IMHA patients, and better understand the role these isoforms play in promoting a
prothrombotic state and predisposing patients to thromboembolic complications.
At this time, the functions of the COX-2 isoform in canine platelets are currently
unknown and additional research is required to better define the role platelet COX-2
plays in hemostasis. The expression of COX-2 in platelets could, like COX-1, contribute
to thromboxane production. Evaluating platelet COX-2 expression in hypercoagulable
patients, with corresponding thromboxane concentrations, would provide a better
understanding of how platelet COX-2 contributes to hemostasis. Similar to the vascular
endothelium, platelet COX-2 could contribute to prostacyclin synthesis and the
prevention of platelet aggregation.
Pre-treatment patient-to-patient variations in platelet COX-2 expression have been
proposed as one potential mechanism for variable aspirin responsiveness. The low dose
aspirin study, however, did not identify a difference in pre-treatment platelet COX-2
expression between the three categories of aspirin responsiveness. Our results suggest
that differences in pre-treatment platelet COX-2 expression do not play a major role in
aspirin resistance in dogs, and indicate that pre-existing COX-2 expression cannot be
used to predict aspirin responsiveness.
During the low dose aspirin study, there was a significant and consistent decrease
in urinary thromboxane concentration, indicating that low dose aspirin is effective at
inhibiting thromboxane generation, despite the fact that the drug did not provide
consistent inhibition of platelet function in all dogs. The high dose of aspirin had a
similar effect on thromboxane concentration, but was able to consistently inhibit platelet
function. One possible explanation for variable inhibition of platelet function despite
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consistent decreases in thromboxane production could be due togenetic polymorphisms in
thromboxane receptors. Platelets express two subtypes of thromboxane receptors, TPα
and TPβ, that originate from the alternative splicing of a gene.11 Genetic differences in
these subtypes of thromboxane receptors could explain why only some patients respond
to the anti-platelet effects of aspirin.
Once stimulated, thromboxane receptors will lead to the activation of
phospholipase C by coupling to several G-proteins, which in turn, increases cytosolic
calcium, activates protein kinase C, and promotes platelet aggregation.11 Previous studies
have suggested that about 70% of canine platelets are insensitive to thromboxane
stimulation.12-14 The thromboxane insensitivity observed in some canine platelets may be
due to impaired platelet thromboxane A2 receptor linked G proteins.14 If only 30% of
dogs have platelets that are sensitive to the effects of thromboxane, this may explain why
only one third of the animals in the low dose of aspirin study responded with a persistent
increase in PFA-100® closure time.
In humans, it has been demonstrated that both thromboxane receptors and ADP
receptors are dependent on receptor linked G proteins and activation of protein kinase C.
It has also been demonstrated that there is a “cross-talk” between these two types of
receptors, so that stimulation of one receptor could result in the desensitization of the
other type of receptor.11 It has been proposed that this cross-talk between receptors could
lead to increased activity of the receptor that has not been inhibited.11 In the dogs that
have platelets that are insensitive to thromboxane-induced activation, other agonists such
as ADP or serotonin may play a more important role in platelet activation, and such dogs
may therefore be relatively resistant to the inhibitory effects of low dose aspirin.
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Cyclosporine administration increases thromboxane synthesis and decreases
platelet expression of both COX-1 and COX-2. Interestingly, this is the opposite pattern
observed in the aspirin studies, where aspirin caused a decrease in platelet thromboxane
production with an increase in platelet COX-1 expression for both doses and COX-2
expression for the low dose. The results of our aspirin and cyclosporine studies, when
considered in combination, suggest that there may be a negative feedback system
between platelet thromboxane production and platelet COX-1 expression. In contrast to
aspirin, platelets exposed to cyclosporine exhibit a decrease in COX-2 expression, a
phenomenon that could possibly be explained by the anti-inflammatory properties of the
medication. Platelet P-selectin and phosphatidylserine expression decreased with
cyclosporine administration, which is not consistent with a cyclosporine-induced increase
in platelet reactivity. The concurrent dramatic increases in urine thromboxane
concentrations however is concerning, suggesting that cyclosporine could induce platelet
activation and potentially predispose to thrombus formation.
The results of these studies have generated many additional questions. It has been
well established that COX-2 is present in megakaryocytes, and its expression can be
altered by a medical condition or drug administration. The change in platelet COX-2
expression, induced or inhibited, could influence platelet function and the coagulation
cascade. A better understanding of the rate and degree of change in COX expression
could better explain aspirin resistance.
We demonstrated that some dogs do not consistently respond to the anti-platelet
effects of low dose aspirin. With the potentially devastating complications of poor
responses to aspirin, it is important to better understand the role aspirin plays in platelet
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function. While platelet-derived thromboxane plays a critical role in vasoconstriction and
promoting platelet aggregation, prostacyclin originating from the vascular endothelium
and mainly through the COX-2 enzyme pathway, could also greatly influence platelet
function. Low dose aspirin, unlike higher anti-inflammatory doses, will alter platelet
function but continue to allow prostacyclin production to continue and contribute to the
prevention of thrombus formation. Analyzing prostacyclin’s role on hemostasis and
platelet function, especially if synthesized by the platelet, may explain why some patients
do not respond to aspirin. Other proposed mechanisms of aspirin resistance include poor
drug bioavailability, alternative sources for platelet activation, and genetic
polymorphisms of platelet glycoproteins and receptors needed to bind collagen.
Interestingly, isoprostanes, which are prostaglandin-like compounds, have been
proposed as a mechanism of aspirin resistance. Isoprostanes are in vivo indicators of
oxidant stress and will be elevated with cardiovascular dysfunction. These molecules are
mainly produced through oxygen free radical induced peroxidation of arachidonic acid,
but unlike prostaglandins, isoprostanes arise through a cyclooxygenase-independent
pathway. 8-iso-prostaglandin F2α will mobilize calcium in platelets and along with 8-isoprostaglandin E2 can initiate platelet activation through the TPα receptor. However, with
inhibition of thromboxane receptors, isoprostanes may stimulate platelet activation
through an alternative pathway.15
For those patients that do not respond to the effects of aspirin, there are several
other medications that could inhibit platelet function. Clopidogrel which irreversibly
blocks the platelet ADP receptor P2Y12, and abciximab which antagonizes the final
common pathway by inhibiting the glycoprotein integrin αIIbβ3, are other anti-platelet
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therapies are slowly becoming popular in veterinary medicine. Several of the techniques
to evaluate platelet function used in these studies could also be used to evaluate these
novel anti-platelet therapies. Monitoring the response to these medications will become
necessary to allow appropriately inhibit platelets, but minimize bleeding complications.
With cyclosporine, our research identified a potentially serious platelet effect that
could influence the rate of thromboembolism in hypercoagulable patients, especially
IMHA patients. Using similar techniques, evaluating the effects of other
immunosuppressive agents, such as azathioprine, mycophenolate, and leufonmide, could
help determine which medications are safe to use in hypercoagulable patients.
Dantrolene, a medication historically used to treat malignant hyperthermia, has recently
been suggested to have immunosuppressive effects on T-lymphocytes, and could provide
a less expensive immunosuppressive option in dogs. Interestingly, dantrolene has also
been shown to inhibit platelet aggregation in rabbits, by inhibition of thromboxane
formation and calcium mobilization.16 If dantrolene is an effective inhibitor of Tlymphocytes and platelets, this medication would be a safe and less expensive therapy for
dogs with IMHA, patients that typically require immunosuppression and anticoagulant
therapies.
Since glucocorticoids have been associated with an increase incidence of
thromboembolism in IMHA patients, determining influences of steroids on platelet
function may help us understand and prevent life-threatening complications such as a
pulmonary thromboembolism (PTE). Naturally occurring hyperadrenocorticism, or
Cushing’s Disease, is a commonly seen endocrinopathy in dogs that is characterized by
excessive secretion of cortisol. It is generally accepted that both humans and dogs that
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are affected with Cushing’s are in a hypercoagulable state and could development a
devastating PTE.17 Since the exogenous administration and the excessive endogenous
production of glucocorticoids could contribute to a hypercoagulable state, the techniques
described in this manuscript could be very useful in evaluating effects of glucocorticoids
on platelet function, and may help us understand and prevent any thromboembolic
complications.
Finally, all of our studies have been performed in healthy dogs. However, the
true evaluation of aspirin and cyclosporine will require evaluation in dogs in proinflammatory states. The next step for these research projects will be to use similar
methodologies in patients with naturally occurring diseases, especially IMHA. Assessing
thromboxane concentrations in IMHA patients receiving cyclosporine could better
determine the safety of the medication, and adding low dose aspirin to the treatment plan
could help us determine if aspirin is capable of counter-acting the pro-inflammatory
effects of cyclosporine. Another potential clinical trial in dogs with naturally occurring
disease would involve the use of an escalating dose of aspirin in procoagulant patients to
determine a dose that will more consistently inhibit platelet function and thromboxane
synthesis, without inhibiting prostacyclin through the COX-2 pathway.
The establishment of different populations of aspirin responders and nonresponders could allow us to better understand the influences of thromboxane receptors
on platelet function. With these different groups, we could evaluate the genetic make-up
of these receptors, allowing us to determine if certain dogs and dog breeds are less
susceptible to the anti-platelet effects of aspirin. The results of these studies would allow
us to determine which anti-platelet therapy and what dose would provide the most
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consistent inhibition of platelet function. If inhibition of thromboxane receptors could
result in an increase in expression of ADP receptors, the use of multiple anti-platelet
therapies may be beneficial to these patients. If multiple medications, or higher than
normal doses, are required to provide consistent preventative therapy, it becomes
important to have an effective and clinically useful ability to assess platelet function. By
combining the techniques used in these studies, we will ideally be able to determine
which drug and dose will provide the most ideal preventative therapy for hypercoagulable
patients and the best method to monitor the effects anti-platelet therapies.
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